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Abstract
A multigenic family of Ca2-binding proteins of the EF-hand type known as S100 comprises 19 members that are
differentially expressed in a large number of cell types. Members of this protein family have been implicated in the Ca2-
dependent (and, in some cases, Zn2- or Cu2-dependent) regulation of a variety of intracellular activities such as protein
phosphorylation, enzyme activities, cell proliferation (including neoplastic transformation) and differentiation, the dynamics
of cytoskeleton constituents, the structural organization of membranes, intracellular Ca2 homeostasis, inflammation, and in
protection from oxidative cell damage. Some S100 members are released or secreted into the extracellular space and exert
trophic or toxic effects depending on their concentration, act as chemoattractants for leukocytes, modulate cell proliferation,
or regulate macrophage activation. Structural data suggest that many S100 members exist within cells as dimers in which the
two monomers are related by a two-fold axis of rotation and that Ca2 binding induces in individual monomers the exposure
of a binding surface with which S100 dimers are believed to interact with their target proteins. Thus, any S100 dimer is
suggested to expose two binding surfaces on opposite sides, which renders homodimeric S100 proteins ideal for crossbridging
two homologous or heterologous target proteins. Although in some cases different S100 proteins share their target proteins,
in most cases a high degree of target specificity has been described, suggesting that individual S100 members might be
implicated in the regulation of specific activities. On the other hand, the relatively large number of target proteins identified
for a single S100 protein might depend on the specific role played by the individual regions that in an S100 molecule
contribute to the formation of the binding surface. The pleiotropic roles played by S100 members, the identification of S100
target proteins, the analysis of functional correlates of S100-target protein interactions, and the elucidation of the three-
dimensional structure of some S100 members have greatly increased the interest in S100 proteins and our knowledge of S100
protein biology in the last few years. S100 proteins probably are an example of calcium-modulated, regulatory proteins that
intervene in the fine tuning of a relatively large number of specific intracellular and (in the case of some members)
extracellular activities. Systems, including knock-out animal models, should be now used with the aim of defining the
correspondence between the in vitro regulatory role(s) attributed to individual members of this protein family and the in vivo
function(s) of each S100 protein. ß 1999 Elsevier Science B.V. All rights reserved.
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1. Introduction
S100 is a multigenic family of low molecular
weight (Mr between 9 and 13 kDa) Ca2-binding
proteins of the EF-hand (i.e. helix-loop-helix) type
comprising 19 members as listed in Table 1 (for re-
views see [1^3]). S100 was discovered in 1965 as a
brain protein fraction [4] which was shown several
years later to consist of two closely related molecules,
S100K (S100A1) and S100L (S100B) [5,6]. Because of
its abundance in the nervous system and owing to
the limited sensitivity of the immunochemical meth-
ods available at that time, S100 was regarded as a
brain-speci¢c protein, restricted to glial cells. In 1981
S100 protein was shown not to be restricted to the
nervous tissue [7]. Since then, hundreds of papers
have described the cellular and subcellular localiza-
tion of classical S100 proteins (S100A1 and S100B)
in a large number of cell types in vertebrates (re-
viewed in [8]). Yet, neither the two above proteins
nor any other member of this family discovered thus
far appear to be ubiquitous [1^3]. In mammals,
S100B is most abundant in glial cells of the central
and peripheral nervous systems, and in melanocytes,
chondrocytes and adipocytes, whereas S100A1 is
most abundant in cardiomyocytes, slow-twitch skel-
etal muscle cells, salivary epithelial cells and renal
cells [1^3,8]. S100A1 has also been detected in hippo-
campal neurons [9], and recent observations indicate
that S100B is expressed in subpopulations of neurons
[10^15]. The other members of the S100 family have
a more restricted tissue and/or cellular distribution,
e.g. lung and kidney (S100A2), ¢broblasts (S100A4,
S100A6, S100A10), myoepithelial cells (S100A4), tu-
mor cells (S100B, S100A4, S100A6), epithelial cells
(S100A7, S100A8, S100A9, S100A10), granulocytes
and monocytes (S100A8, S100A9, S100A12, and
the S100A8-like protein CP-10), smooth and heart
muscle cells (S100A2, S100A4, S100A6, S100A11),
placenta (S100P), granular cells of the epidermis
(pro¢laggrin, trychohyalin, repetin) (reviewed in
[3]). Taken together, these data suggest that individ-
ual S100 proteins might have speci¢c functional roles
in the cell types where they are expressed. Because of
their non-ubiquity and their up-regulation in speci¢c
tumor cells several S100 proteins are being used in
diagnostic pathology [8,16^23].
Interestingly, three epidermal proteins, pro¢lag-
grin, trichohyalin, and repetin (Rptn) with ability
to bind keratin intermediate ¢laments (IFs) and im-
plicated in the regulation of keratin IF lateral asso-
ciation, contain EF-hand Ca2-binding domains
within a sequence exhibiting high identity with other
members of the S100 family [24^27]. These three
proteins are thought to represent fused genes of the
corni¢ed cell envelope precursor protein genes and
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have been regarded as a subgroup of the S100 pro-
tein family [3].
Preceded by the observation that Ca2 was capa-
ble of inducing conformational changes in classical
brain S100 protein (mixture of S100A1 and S100B)
and that Ca2 and K had antagonizing e¡ects on
S100 conformation [28], between 1978 and 1981
came the ¢ndings that brain S100 actually is a mix-
ture of two closely related protein species, S100A1
and S100B (formerly known as S100K and S100L,
respectively); that S100A1 and S100B form the ho-
modimers S100A12 and S100B2 (formerly termed
S100ao and S100b, respectively) as well as the
S100A1/S100B heterodimer (formerly termed
S100a); and that each monomer contains a canonical
Ca2-binding site of the EF-hand type in its C-ter-
minal half and a non-conventional (longer and rear-
ranged) EF-hand Ca2-binding site in its N-terminal
half [5,6].
The Ca2-binding properties of individual S100
proteins have been documented by a number of ex-
perimental approaches, including intrinsic £uores-
cence spectroscopy, equilibrium dialysis with
45Ca2, gel overlay with 45Ca2, circular dichroism,
and £uorescence spectroscopy with derivatized pro-
teins [1^3]. There is consensus that the Ca2-binding
a⁄nity of classical S100 proteins in solution is low
under physiologic ionic conditions, and that this af-
¢nity increases by several orders of magnitude in the
presence of S100 targets. Actually, in many cases the
interaction of an S100 protein with its target pro-
tein(s) and regulatory e¡ects of an S100 protein on
cellular activities were observed to occur at free Ca2
concentrations signi¢cantly lower than those at
which half-maximal binding of Ca2 to an S100 pro-
tein in solution was detected [1^3]. All these obser-
vations point to the occurrence of large conforma-
tional changes and/or a variety of conformational
states in S100 proteins in the presence of Ca2 and/
or S100 target proteins [1^3,29,30]. As an exception
to the rule that S100 proteins undergo conformation-
al changes in the presence of Ca2, S100A10 (for-
merly known as p11 or calpactin I light chain) [31^
33] does not bind Ca2 and does not undergo Ca2-
induced conformational changes [31^33]. This pro-
tein, which is considered to be in a permanent
‘Ca2-on state’, exists as a homodimer that function-
ally crosslinks two copies of annexin II (a member of
a multigenic family of Ca2-dependent phospholip-
id-, membrane- and cytoskeleton-binding proteins
[34,35]) to form the annexin II2-S100A102 heterote-
tramer (also known as calpactin I) irrespective of the
presence or absence of Ca2 [31^33,36]. Mutations
and deletions in an ancestral S100 gene resulted in
locking S100A10 in an active, Ca2-insensitive con-
formation. However, S100B also may exist in a
Ca2-insensitive state [37,38] and Ca2-independent
binding of S100A1 with certain target proteins has
been documented [39]. In general, however, S100
proteins are suggested to function as Ca2 sensor
proteins that, with a few exceptions (see Section
2.2), undergo Ca2-dependent conformational
changes. These latter result in the exposure of a bind-
ing surface through which S100 proteins interact
with target proteins, as is the case with other Ca2
sensor proteins (e.g. calmodulin and troponin C).
Thus, those S100 proteins that undergo Ca2-in-
duced conformational changes and interact with tar-
get proteins in a Ca2-dependent manner reasonably
play a role in Ca2 signal transduction. S100A1 and
S100B also bind Zn2 with a rather high a⁄nity [1^
3]. Ca2 binding to Zn2-loaded S100A1 and S100B
occurs with a signi¢cantly higher a⁄nity [1^3]. Zn2
binding was also reported for S100A3 (S100E),
S100A6 (calcyclin), S100A8, the S100A8-like protein
CP-10, S100A9 (MRP14) and S100A12 (calgranulin
C) [1^3,40,41]. Finally, recent evidence indicates that
S100B also binds copper [42].
Among the various second messengers Ca2 prob-
ably is the most ancient and energetically inexpensive
[43]. The rise in cytoplasmic Ca2 is a universal sig-
nal that controls a variety of processes in eukaryotic
cells (e.g. cell growth and di¡erentiation, cell motil-
ity, muscle contraction, gene expression, secretion,
nerve impulse transmission, apoptosis). Cells have
evolved a battery of intracellular Ca2-binding pro-
teins, among which are S100 proteins, that act to
transduce the Ca2 signal [44,45]. S100 proteins
have been identi¢ed in and puri¢ed from vertebrate
tissues [1^3]. Although an S100B-like protein has
been immunologically detected in some invertebrates
and in spinach leaves [1,8,46], there is no de¢nite
evidence that members of the S100 protein family
are expressed in invertebrates and/or in plants. The
available genomic databases for plants, yeast, the
nematode Caenorhabditis elegans, and Drosophila
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demonstrate that S100 proteins are not expressed in
these organisms.
Several reviews have appeared on S100 proteins in
the last decade dealing with the tissue, cellular and
subcellular distribution of these proteins, their func-
tional properties, the structure and chromosomal lo-
calizations of their genes, and implications of some
S100 proteins in the pathophysiology of several dis-
eases [1^3,8,47^49]. Some of these reviews also have
discussed an emerging aspect of the S100 protein
biology, i.e. the release of some S100 members by
de¢nite cell types and the ability of released S100
proteins to modulate certain activities in target cells.
In the present review functional aspects of S100 pro-
teins will be commented on also in light of recent
observations on novel regulatory e¡ects of some
S100 proteins and the tertiary and quaternary struc-
ture of S100A6, S100B, S100A7 (psoriasin) and
S100A10. The aim of the present review is two-
fold, describing the state-of-the-art of the S100 pro-
tein story and pointing to those regulatory functions
of S100 proteins that are likely to occur in vivo.
Concerning the latter point, the following criteria
have been used in this review to establish intracellu-
lar and/or extracellular functions of S100 proteins:
(i) identi¢cation of the S100-binding site on a target
protein and/or the binding site for a target protein on
an S100 protein; (ii) functional correlates of S100
protein-target protein interactions; (iii) identi¢cation
of regulators of S100 protein-target protein interac-
tions; (iv) cellular and subcellular colocalization of
an S100 protein and its target protein(s); (v) co-im-
munoprecipitation of S100 protein-target protein
complexes; (vi) e¡ects of inhibition of S100 protein
synthesis or of overexpression of S100 protein; (vii)
identi¢cation of the mechanism of S100 protein re-
lease to the extracellular space; (viii) identi¢cation of
the S100-binding site(s) on S100 protein target cells;
and (ix) identi¢cation of the intracellular signalling
pathways activated upon interaction of an S100 pro-
tein with its target cell(s).
2. S100 proteins form dimers: functional implications
2.1. Disul¢de crosslinked S100 dimers
Most of S100 proteins have a strong tendency to
dimerize. In particular, under non-reducing condi-
tions, like those found in the extracellular space,
S100B can form disul¢de crosslinked homodimers
[50,51], an event that appears to be facilitated by
the presence of high Ca2 concentrations and/or lip-
ids [52]. S100A10, S100A2 (S100L) and S100A6 also
form disul¢de crosslinked dimers [53^56]. The pres-
ence of two cysteines at positions 68 and 84, that is
typical of S100B [5,51], is essential to the formation
and the biological activities of disul¢de crosslinked
S100B2 dimers [51]. Although the presence of S100B
in the extracellular space in mature tissues (brain)
has been documented in but one report [57], secre-
tion of this protein by cultured astrocytes has been
reported as has been secretion of S100A2, S100A7,
S100A8 (MRP8), the S100A8-like protein CP-10,
and S100A9 (MRP14) by speci¢c cell types [58^61]
(see Section 3.2).
2.2. S100 proteins form dimers within cells
It is now established that S100A1, S100B, S100A6,
S100A7 S100A10 and S100A11 (S100C) form homo-
dimers and that S100A1/S100B and S100A8/S100A9
heterodimers can form even under reducing condi-
tions, i.e. within cells, and that in at least S100 ho-
modimers the two subunits are held together by non-
covalent bonds [62^67]. S100A82/S100A9 trimers and
S100A82/S100A92 tetramers also form in vivo [62].
Ca2 appears to strongly stimulate the formation
of the S100A8/S100A9 heterodimer [62]. Probably,
most of S100 proteins can form homodimers (with
the exception of calbindin D9k and, presumably, pro-
¢laggrin, trichohyalin, and repetin) [63^67]. Recent
observations on the structure of S100A6, S100B
and S100A7 in the absence of Ca2, as investigated
by NMR spectroscopy, X-ray crystallography, or
multiple anomalous wavelength dispersion, indicate
that S100A6, S100B and S100A7 homodimers, and,
by analogy, most of the members of the S100 protein
family that dimerize are characterized by a symmet-
ric homodimeric fold not found in other Ca2-bind-
ing proteins [63^67] (Fig. 1). These studies also in-
dicate that dimerization of these proteins is mediated
by hydrophobic contacts through individual helices
IV (in an S100 monomer, helix IV is located just next
the conventional Ca2-binding loop found in the C-
terminal half), and that residues at the C-termini of
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helix I (which precedes the non-conventional Ca2-
binding loop in the N-terminal half) and residues in
the C-terminal extension of individual subunits con-
tribute to the dimer interface. The S100B dimer (and,
by analogy, all other S100 homodimers) appears
highly stable (dimerKd6 500 pM) because of the large
number of hydrophobic residues in the dimer inter-
face [68], suggesting that within cells most of S100
proteins do not exist as monomers (also see below).
The two monomers in the apo S100A6, the apo
S100B and the apo S100A7 dimers are related by a
two-fold axis of rotation. It is suggested that the
mode of dimer formation in the cases of S100A6
and S100B and S100A7 applies to all the S100 pro-
teins that dimerize [63,64]. The above studies [63,64]
have identi¢ed two regions in individual S100 sub-
units that might be implicated in the formation of a
binding region for S100 target proteins, the C-termi-
nal extension and the hinge region. It is known that
the C-terminal extension of S100A10 is implicated in
the binding of its natural ligand, annexin II [69]. In
one study [70], the C-terminal extension of S100A1
has been shown to be important for the binding of a
synthetic peptide, TRTK-12, derived from a se-
quence found in the K subunit of the actin capping
protein, CapZ, an S100A1- and S100B-binding pro-
tein [71,72] (Table 1), suggesting that the C-terminal
extension of S100A1 (and, likely, S100B) is impli-
cated in the recognition of CapZ. However, in an-
other study residues in the C-terminal helix (helix IV)
and residues V-8 to D-12 of the N-terminal helix
(helix I) of S100B have been shown to be a¡ected
by TRTK-12, by NMR spectroscopy [73]. Since in
the Ca2-free S100B dimer the N-terminal helix of
one monomer passes close to the C-terminal helix of
the opposite monomer [64,65], the C-terminal helix
and the N-terminal helix of opposite monomers were
suggested to form a discontinuous epitope acting as
the CapZ-binding site on S100B (and, likely,
S100A1) [73].
The major change induced by Ca2 in S100B is a
remarkable change of the interhelical angle between
helices III and IV which £ank the canonical Ca2-
binding loop in the C-terminal half of S100B [66,74^
77]. This change exposes a cleft, de¢ned by residues
in the hinge region, helices III and IV, and the C-
terminal extension, which is buried in apo S100B and
might thus be important for binding target proteins
in the presence of Ca2. Also, the Ca2-induced
change in the position of helix III of S100B causes
signi¢cant changes in the structure and orientation of
Fig. 1. Structure of the Ca2-loaded (A) and Ca2-free (B)
S100B2 dimer. One S100B monomer is in yellow and the other
one is in blue. Helices are indicated by Roman numerals (I^IV
in one monomer, and IP^IVP in the other monomer). Binding of
Ca2 to each S100B monomer causes a reorientation of helix
III relative to all other helices with consequent reorientiation of
the hinge region (H). These changes result in the exposure to
the solvent of a surface de¢ned by residues (in magenta) in heli-
ces III and IV, the hinge region and the C-terminal extension
[75]. Residues in helix I of the other monomer (IP) could also
take part in the generation of the binding surface, as suggested
by others [66,73]. Calcium ions are represented by light-pink
dots within Ca2-binding loops (L1, L2 in one monomer, and
L1P, L2P in the other monomer). Note that the Ca2-loaded
S100B2 dimer is more extended than the Ca2-free dimer. Re-
produced, with some additions, with permission from Fig. 7 in
[75].
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Table 1
Summary of members of the S100 protein family and their target proteins, and suggested functions
Protein Target proteins, references Suggested functions, references
S100A1 CapZK [72], desmin [83,85], GFAP [84,85],
p53 [88], annexins V and VI [96], tubulin
[101,121], d proteins [108,109], MyoD [111,132],
E12 [132], fructose-1,6-bisphosphate aldolase
[133], glycogen phosphorylase [134],
phosphoglucomutase [135], twitchin kinase
[136,137], Ndr [142], adenylate cyclase [144],
membrane-bound guanylate cyclase
[146^148,151], ryanodine receptor [158], F-actin
[226]
Inhibits type III intermediate ¢lament [83^85,179] and microtubule
assemblies [120,121,123,160^162,176] ; inhibits protein
phosphorylation [88^92,106^111]; inhibits glycogen phosphorylase
[134] and phosphoglucomutase [135] activities and stimulates aldolase
[133], adenylate cyclase [144], guanylate cyclase [146^148,151],
twitchin kinase [136,137] and Ndr kinase [142] activities; stimulates
Ca2-induced Ca2 release [156,158]; regulates transcription factors
[111,131,132]
S100A2 Tropomyosin [103], F-actin [226] Regulates F-actin-tropomyosin interactions [103]; suppresses tumor
progression [353^355]; once secreted, chemoattracts eosinophils [59]
S100A3
S100A4 Myosin [130,220^225,348,349], F-actin
[222,225,226], tropomyosin [222]
Inhibits myosin phosphorylation [130]; confers Ca2-sensitivity to
tropomyosin regulation of actomyosin ATPase activity [222]; plays a
role in metastatic invasiveness [130,341^349]
S100A5
S100A6 Tropomyosin [56], annexins II [82] and XI
[71,94], glyceraldehyde-3-phosphate
dehydrogenase [82], caldesmon [227]
Blocks the caldesmon-dependent inhibition of actomyosin ATPase
activity [227]; regulates cell-cycle progression [333]
S100A7 Once secreted, chemoattracts CD4 lymphocytes [60]
S100A8 Microtubule protein [61]; vimentin [207,209],
keratins [211,212]
Inhibits casein kinase II activity [152]; regulates myeloid cell
maturation and function [152^154]; contributes to macrophage
activation [212^214]; in the form of an S100A8/S100A9 complex
binds unsaturated fatty acids likely to modulate their pro-
in£ammatory activity [302,303] ; once secreted and in the form of an
S100A8/S100A9 complex displays cytostatic [293,294] and
antimicrobial [295] activities, inhibits macrophage activation [297] and
immunoglobulin synthesis [298] by lymphocytes
S100A8-like,
CP-10 protein
Once secreted, chemoattracts leukocytes [286^288,290,291]
S100A9 Microtubule protein [61]; vimentin [207,209],
keratins [211,212]
Inhibits casein kinase II activity [152]; regulates myeloid cell
maturation and function [152^154]; contributes to macrophage
activation [212^214]; in the form of an S100A8/S100A9 complex
binds unsaturated fatty acids likely to modulate their pro-
in£ammatory activity [302,303] ; once secreted and in the form of an
S100A8/S100A9 complex displays cytostatic [293,294] and
antimicrobial [295] activities, inhibits macrophage activation [297] and
immunoglobulin synthesis [298] by lymphocytes
S100A10 Annexin II [31^33,36,185^187,200], 85-kDa
phospholipase A2 [155], unidenti¢ed proteins
of the corni¢ed envelope [199], plasminogen
[310]
Targets annexin II to membranes and F-actin [31^36,117,200];
in the form of the annexin II2-S100A102 complex crossbridges
F-actin to membranes [31^36,190]; inhibits annexin II
phosphorylation [114^116]; stimulates F-actin bundling [117,190,191];
enhances the stimulatory e¡ect of annexin II on GFAP assembly
[126,127]; inhibits 85-kDa phospholipase A2 activity [155]; regulates
exocytosis and endocytosis (in the form of the annexin II2-S100A102
heterotetramer) [188,189,193]; contributes to the formation of the
corni¢ed envelope in epidermal keratinocytes [199]; stimulates t-PA
plasminogen activation [310]
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the hinge region and the C-terminal extension
[66,74,75]. These data appear to con¢rm the previous
suggestion that the hinge region and the C-terminal
extension might take part in the formation of a bind-
ing surface for the recognition of S100B target pro-
teins [48,64]. However, whereas there is a substantial
agreement between NMR spectroscopy and crystal-
lography data about the structure of apo and Ca2-
bound S100B [66,74,75,77], it was suggested that an
S100B dimer would bind a target protein through a
site made of helix IV of one monomer and helix IV
of the other monomer [66]. This mode of interaction
would predict a binding stoichiometry of 1 mol of
ligand/mol of S100B2 dimer [66], which is not the
case. Actually, in those instances where binding of
a target protein to an S100 protein had been accu-
rately determined, a binding stoichiometry of 2 mol/
mol of S1002 has been reported (see above and be-
low). However, other modes of S100 protein interac-
tion with target proteins cannot be excluded. For
instance, the S100A7 dimer has been suggested to
wrap around its target proteins through individual
C-terminal halves [67]. Di¡erences in the S100A7 se-
quence (which is only V27% homologous to that of
S100B) as well as in the reorientation of S100A7
helices might be responsible for di¡erences in the
mode of target protein recognition in S100A7 [67].
However, no data are available about S100A7 target
proteins. Recent observations have implicated both
the hinge region and the C-terminal extension of
S100B in the interaction with and the activation of
a membrane-bound guanylate cyclase activity as well
Table 1 (continued)
Summary of members of the S100 protein family and their target proteins, and suggested functions
Protein Target proteins, references Suggested functions, references
S100A11 Annexin I [86,95,203], proteins of the corni¢ed
envelope likely including annexin I [199]
Inhibits annexin I phosphorylation [86,95], ; contributes to the
formation of the corni¢ed envelope in epidermal keratinocytes likely
in the form of an annexin I2-S100A112 heterotetramer [199,203] ; in
the form of an annexin I2-S100A112 heterotetramer has a role in
endocytosis [204]
S100A12
S100A13 Fibroblast growth factor-1/synaptotagmin
aggregate [309]
Participates in ¢broblast growth factor-1 release [309]
S100B Tubulin [38,101,122,166], GFAP
[38,84,85,112,179,196], vimentin [38,166],
CapZK [71], retinal phosphoprotein p80 [78],
desmin [83,196], p53 [88], neuromodulin (GAP-
43) [90^92], neurogranin [92], MARCKS
[92,106], annexins V [96], VI [96] and II
[102,107], d proteins [108,109], caldesmon
[110,124,125,219], MyoD [111,132], E12 [132],
fructose-1,6-bisphosphate aldolase [133],
phosphoglucomutase [135], twitchin kinase
[136], Ndr [142], adenylate cyclase [143],
membrane-bound guanylate cyclase
[146^148,151], calponin [218]
Inhibits protein phosphorylation [78,87^92,107^112]; inhibits type III
intermediate ¢lament [83^85,179] and microtubule [120,121,123,160^
162,176] assemblies; regulates cell-cycle progression likely via
interaction with transcription factors [88,111,132,271,311^313] ; blocks
the caldesmon [124,125]- and calponin [218]-dependent inhibition of
actomyosin ATPase activity; inhibits fetal protein (K-actin and L-
myosin) expression in striated muscle cells [131]; stimulates aldolase
[133], phosphoglucomutase [135], Ndr kinase [142], adenylate cyclase
[143], and guanylate cyclase [146^148,151] activities ; once secreted,
stimulates neurite outgrowth [50,51,236^239,241^244,272] and
astrocyte proliferation [245] by enhancing Ca2 £uxes [249] (at nM
concentrations) or is toxic to neurons [267^270] and astrocytes [270]
(at WM concentrations), participates in the pathophysiology of
neurodegenerative disorders [250^262,284], participates in long term
potentiation and memory processes [273^284]; inhibits cytotoxic
lymphocyte proliferation and IFN-Q secretion [296]
S100P
Calbindin 3
(D9k)
Bu¡ers cytosolic Ca2 [104]
Pro¢laggrin Keratins [24,26] Regulates lateral association of keratin intermediate ¢laments [24,26]
Trychohyalin Keratins [25] Regulates lateral association of keratin intermediate ¢laments [25]
Repetin Keratins [27] Regulates lateral association of keratin intermediate ¢laments [27]
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in the interaction of S100B with the retinal phospho-
protein, p80 [78]. Moreover, a recombinant S100A1
lacking the last nine residues was reported to be un-
able to interact with phenyl-Sepharose and TRTK-12
[39]. Also recently, it was found that a recombinant
S100A1 lacking the C-terminal extension has no or a
remarkably reduced ability to interact with a number
of S100A1 (and S100B) target proteins, e.g. glial ¢-
brillary acidic protein (GFAP) and tubulin as well as
with the TRTK-12 peptide and a peptide derived
from the tumor suppressor protein p53 [79], which
again points to an important role of the C-terminal
extension in Ca2-dependent, target protein recogni-
tion by S100A1 and, by analogy, S100B.
Discrepancies concerning the S100B regions impli-
cated in target recognition, as outlined above, might
be settled in light of recent X-ray crystallography
data on the structure of S100A10, which, as men-
tioned above, is considered to be in a permanent
‘Ca2 on’ state [31^33,36,69]: the hinge region and
the C-terminal helix/extension of one monomer and
the N-terminal helix of the other monomer would
constitute a binding surface for the recognition of
annexin II [80]. In this respect, the similarity between
the structure of the S100A102 dimer (see Fig. 1A in
[80]) and that of Ca2-loaded S100B2 and S100A62
dimers (see Fig. 1C in [77] and Fig. 5B in [75], and
Fig. 1A in [76], for S100B and S100A6, respectively)
is remarkable. All the above observations would also
explain the reason why S100 members that act to
transduce the Ca2 signal form homodimers and,
eventually, heterodimers: regions of both monomers
would contribute to generate their functional binding
sites. In the case of S100A6 no major Ca2-induced
structural changes were concluded to occur, raising
questions about the proposed roles of S100 proteins
as Ca2 sensor proteins implicated in signal trans-
duction [76]. Yet, the orientations of the hinge re-
gion, helix III and the C-terminal extension in
S100A6 appear to be a¡ected by Ca2 binding [76],
suggesting that in S100A6 also a binding surface,
which is buried in the apo state, is exposed to the
solvent in the Ca2-bound state. Di¡erences in the
primary sequences of S100B and S100A6, as well as
di¡erences in the length of the hinge region and the
C-terminal extension in these proteins [48], might
explain the speci¢city of target protein binding. Ac-
tually, while there is no information as to whether or
not annexin XI and glyceraldehyde-3-phosphate de-
hydrogenase, two known S100A6 target proteins
[81,82] (Table 1), also interact with S100B, it has
been reported that S100A6 does not compete with
S100A1 and S100B for binding to desmin [83].
The IF subunits, GFAP and desmin, two other
S100A1- and S100B-binding proteins [83,84] (Table
1), likely interact with the TRTK-12-binding site on
S100B and S100A1 since TRTK-12 blocks both these
interactions and the inhibitory e¡ects of S100A1 and
S100B on GFAP assembly [85] and desmin assembly
(unpublished data) into IFs. Also, the C-terminal
extension of S100A11 is implicated in the binding
of annexin I [86] (Table 1). Thus, it is possible that
the C-terminal extension of any S100 member that
acts as a Ca2 sensor protein is implicated in the
interaction with one or more targets. In addition,
the hinge region, which connects the N-terminal
half to the C-terminal half in any S100 protein, could
also be implicated in the recognition of de¢nite target
proteins [63,64,75^77,87]. A synthetic peptide corre-
sponding to the S-367 to E-388 C-terminal sequence
of p53, which was proposed to contain the S100B-
binding site on p53 and to correspond to the p53
phosphorylation site by protein kinase C (PKC)
[88] (Table 1), binds to S100B in a Ca2-dependent
manner [87]. Residues S-41, L-44, E-45, E-46 and I-
47 in the hinge region, V-52, V-53, V-56 and T-59 in
helix III, and A-83, C-84, H-85, E-86 and F-87 in the
helix IV/C-terminal extension appear to be impli-
cated in the Ca2-dependent p53 peptide binding to
and/or re£ect structural changes in S100B, as inves-
tigated by NMR spectroscopy [87]. Binding of S100B
to the p53 peptide also inhibits its phosphorylation
[89]. Interestingly, S100B also binds to and inhibits
the phosphorylation of a peptide derived from neu-
romodulin [89], an S100B target protein [90^92] (Ta-
ble 1), and the regulatory domain of PKC [89]. These
three peptides display a certain amount of sequence
identity [89] with the CapZK peptide, TRTK-12, sug-
gesting that S100B can bind to proteins that possess
the consensus sequence found in CapZK (i.e. (K/
R)(L/I)XWXXIL), and that target proteins display-
ing this feature may be S100B-binding proteins.
Recent observations indicate that the p53 peptide
also interacts with S100A1; that the S100A1 C-ter-
minal extension plays a major role in this interac-
tion; and that the p53 peptide blocks the S100A1
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binding to GFAP and tubulin, and the inhibitory
e¡ect of S100A1 on GFAP polymerization [79]. All
these ¢ndings suggest that the functional binding site
on S100A1 and S100B monomers may be similar and
that a number of S100A1 and S100B target proteins
might share a common binding site on S100A1 and
S100B. In further support of the possibility that the
hinge region has a role in the formation of a binding
surface on S100 proteins is the observation that a
synthetic peptide derived from the hinge region of
the S100A8-like CP-10 protein, a chemotactic pro-
tein, exhibits chemotactic properties similar to those
of full-length protein [93] (Table 1). On the other
hand, the N-terminal region (helix I) of S100A6
has been suggested to be essential for the binding
of glyceraldehyde-3-phosphate dehydrogenase [81]
and an annexin XI isoform [81,82,94] (Table 1). He-
lix I of one S100A6 monomer could contribute to the
generation of a binding surface together with resi-
dues in helices III and IV and the hinge region of
the other monomer (see Fig. 1 in [76]).
The lack of extensive sequence homology between
annexins I, II and XI (the target proteins in the cases
of S100A11, S100A10 and S100A6, respectively) (Ta-
ble 1), on the one hand, and the K subunit of CapZ,
GFAP, desmin, neuromodulin, tubulin, neurogranin,
and p53 (which are S100A1 and S100B target pro-
teins Table 1), on the other hand, and the target
speci¢city reported for many S100 proteins (Table
1) suggest that individual components of the surface
exposed to the solvent upon Ca2 binding to S100B
and S100A6 (and, likely, other S100 proteins) might
play di¡erential roles in the recognition of target
proteins. For instance, this would explain the obser-
vations that the C-terminal extension of S100A11 in
one report [86] and the N-terminal helix of S100A11
in another report [95] were implicated in annexin I
binding; that deletion of the N-terminal helix of
S100A6 abolishes the glyceraldehyde-3-phosphate
dehydrogenase [82] and annexin XI [81] binding;
and that the chemotactic potency of the synthetic
peptide derived from the hinge region of the
S100A8-like protein, CP-10, is much smaller than
the full-length protein [93]. Probably, this might
also explain recent observations on annexin VI bind-
ing to S100A1 and S100B and annexin VI blockade
of the inhibitory e¡ects of S100A1 and S100B on
desmin and GFAP assemblies into IFs (Table 1):
whereas there seems to be no major competition be-
tween annexin VI and desmin/GFAP for binding to
either S100 protein, occupation of the annexin VI
site alters the properties of the desmin or GFAP
site and vice versa [96]. Also, whereas deletion of
S100A1 C-terminal extension strongly reduces or
abolishes the interaction of S100A1 with the
GFAP, desmin, and tubulin [79], deleted S100A1 still
binds annexin VI in a Ca2-dependent manner (un-
published observations). On the other hand, S100B
has been recently proposed to interact with its target
proteins through more than one site [97] and S100A1
has been suggested to utilize di¡erent mechanisms
(i.e. di¡erent regions) for interacting Ca2-depend-
ently with some target proteins and Ca2-independ-
ently with some other target proteins (e.g. muscle-
speci¢c aldolase A) [39]. However, no information
is available at present about the region(s) of
S100A1 (and, likely, S100B) that are implicated in
the Ca2-independent interaction of these proteins
with certain target proteins, aside from the observa-
tion that the C-terminal part of helix IV and the C-
terminal extension are not required for Ca2-inde-
pendent binding of S100A1 to aldolase A [39].
In conclusion, the available evidence indicates that
the binding surface that is exposed upon Ca2 bind-
ing to S100A6 and S100B (and eventually several
other S100 members) might accommodate the bind-
ing a number of target proteins, with the di¡erent
portions of the S100 molecule that have been impli-
cated in the formation of the binding surface being
more or less important depending on the target con-
sidered. Clearly, this mode of Ca2-dependent inter-
action of S100 proteins with their target proteins is
quite di¡erent from that of calmodulin and troponin-
C [98^100]: individual monomers in an S100 dimer
open up to accommodate the target protein binding
with resulting elongation of the whole dimer [75]
(Fig. 1) (also see Fig. 3A in [76] and Fig. 5 in [66]).
The location of target protein-binding sites on oppo-
site sides of S100 homodimers (and, possibly, heter-
odimers) would permit an S100 dimer to crossbridge
two homologous or heterologous S100 target pro-
tein. Examples of this are the annexin II2-S100A102
and annexin I2-S100A112 heterotetramers [31^
33,36,86] (Table 1). Also, the stoichiometry of
S100A1 and S100B binding to desmin, GFAP, tubu-
lin, CapZ and p53 (1 mol of S100A1 or S100B/mol
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of desmin, GFAP, tubulin, CapZ or p53)
[71,72,83,84,101] suggests that each of the above
S100A1 or S100B target proteins may bind to oppo-
site sides on each S100A1 or S100B dimer. The same
would apply to the S100A6/glyceraldehyde-3-phos-
phate dehydrogenase complex [82], the S100B/annex-
in II complex [102], the S100A6/annexin XI complex
[81], the S100A2/tropomyosin complex [103], and the
S100A1 or S100B/annexin VI and S100A1 or S100B/
annexin V complexes [96].
Calbindin D9k is the only S100 member identi¢ed
so far that does not form dimers, acting as a Ca2
modulator, rather than a Ca2 sensor protein ([104]
and references therein) (Table 1). This protein bu¡ers
cytosolic Ca2 and no target proteins for it have
been identi¢ed, implying that it is implicated in
Ca2 signal transduction to the extent to which it
bu¡ers cytosolic Ca2. The shorter helices I and IV
and hinge region in calbindin D9k and the smaller
hydrophobic surface that becomes exposed upon
Ca2 binding, as compared to other S100 proteins
(see Fig. 3 in [66]), might be responsible for the in-
ability of calbindin D9k both to form dimers and to
interact with target proteins.
Recent crystallographic structure determinations
suggest that, in addition to homodimers, S100A10
forms homotetramers in which the two homodimers
are antiparallely connected via disul¢de bridges be-
tween pairs of the C-61 residues of one each of the
two S100A10 copies that form an S100A102 dimer,
both in the absence and in the presence of the annex-
in II N-terminal tail [80]. However, information is
lacking about functional implications of S100A10
tetramer formation.
A recent structural study of S100A8 and S100A9
suggests that S100A82 and S100A92 homodimers
form independently of the absence or presence of
Ca2, and that in solution containing both proteins
S100A8 and S100A9 display a strong preference to
associate as heterodimers [105]. It is suggested that
the two monomers of the heterodimer are related by
a two-fold axis of rotation, as is the case with
S100A62, S100B2, S100A72 and S100A102 dimers,
that the functionally relevant form of S100A8
and S100A9 is a heterodimer, and that functional
roles attributed to individual S100A8 and S100A9
proteins rely on formation of stable homodimers
[105].
3. Putative functions of S100 proteins
Extensive work done in several laboratories has
implicated S100 proteins in both intracellular and
extracellular activities [1^3,8,47^49] (Table 1).
3.1. Intracellular functions of S100 proteins
3.1.1. Regulation of protein phosphorylation
Ca2-dependent and, in two cases, Ca2-independ-
ent inhibition of protein phosphorylation by S100
proteins in vitro has been documented since 1982
[1^3]. This inhibition results from a direct interaction
of S100 proteins with kinase substrates rather than
with kinases. Among the proteins whose phospho-
rylation is inhibited by S100 proteins are the myris-
toylated alanine-rich C kinase substrate (MARCKS)
also known as 87-kDa protein [106], neuromodulin
(GAP-43) [90^92], annexin II [107], and neurogranin
[92], microtubule-associated d proteins [108,109], cal-
desmon [110], MyoD [111], p53 [88,89], GFAP and
vimentin [112], and the MARCKS-like retinal phos-
phoprotein p80 [78] (in all these instances S100A1
and/or S100B are the S100 members implicated),
and annexins I and II, the phosphorylation of which
is inhibited by their ligands, S100A11 and S100A10,
respectively [86,95,113^116] (Table 1). However, the
functional correlates of S100 protein-dependent in-
hibition of protein phosphorylation are not fully elu-
cidated.
S100B-dependent inhibition of the tumor suppres-
sor protein p53 phosphorylation might be part of
S100B-dependent protection of p53 (see Section
3.2.2).
Changes in the phosphorylation state of annexins I
and II might alter the association of these proteins
with their targets (reviewed in [34,35,117]) (also see
Section 3.1.4).
MARCKS is abundant in neurons [106] and was
proposed to crosslink actin to membranes. In princi-
ple, in those neurons that have been reported to ex-
press S100A1 and/or S100B [10^15], these latter pro-
teins might intervene in the regulation of the
proposed role of MARCKS as an actin-crosslinking
factor via inhibition of its phosphorylation (but no
information is available at present in this respect).
Phosphorylation of d proteins might represent a
means to control MT formation (phosphorylation
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of MT-associated proteins results in a decreased abil-
ity of these proteins to promote tubulin polymeriza-
tion into MTs [118,119]). In this context, inhibition
of d protein phosphorylation by S100A1 and S100B
might contribute to the regulation of the state of
assembly of MTs (Table 1). These ¢ndings would
complement in vitro studies showing that S100A1
and S100B inhibit tubulin polymerization [120,121]
by binding to unassembled tubulin [101,122] and
stimulate MT disassembly by increasing the Ca2-
sensitivity of preformed MTs [123] (see Section
3.1.4) (Table 1).
S100A1 and/or S100B binding to caldesmon (a
cytoskeletal protein abundant in smooth muscle cells
and expressed in other cell types) and the ensuing
inhibition of caldesmon phosphorylation results in
reversal of caldesmon-dependent inhibition of acto-
myosin ATPase activity [110,124,125] (Table 1). Yet,
no data are available on colocalization of S100A1
and/or S100B with caldesmon.
Inhibition of GFAP and vimentin phosphorylation
by S100B might re£ect interaction of S100B with a
stretch of residues in the N-terminal domain of the
above IF subunits [85] (also see Section 3.1.4).
S100A10 inhibits annexin II phosphorylation [114^
116] (Table 1). As anticipated, S100A10 forms a het-
erotetrameric complex with annexin II in which an
S100A102 dimer crossbridges two copies of annexin
II [31^33,36]. This complex interacts with arti¢cial
membranes, promotes chroma⁄n granule aggrega-
tion and fusion, bundles F-actin, and rescues the
ability of GFAP to assemble into IFs at pH values
s 6.7 in a Ca2-dependent manner [34,35,117,
126,127]. S100A10 colocalizes with annexin II [35].
Phosphorylated annexin II2-S100A102 requires a
higher Ca2 concentration for inducing lipid vesicle
aggregation and does not bind F-actin, but its bind-
ing to lipid vesicles and chroma⁄n granules remains
unchanged [34,35,117]. In one case, annexin II2-
S100A102 phosphorylation by PKC was reported to
result in dissociation of the annexin II2-S100A102
complex and in a striking annexin II-dependent stim-
ulation of chroma⁄n granule fusion [128]. These
data indicate that S100A10 regulates the annexin II
activities which, in turn, depend on the phospho-
rylation state of annexin II (also see Section 3.1.4).
Although S100A1 and/or S100B also inhibit annexin
II phosphorylation in a Ca2-independent manner
like S100A10 [107], but bind annexin II in a Ca2-
dependent manner [102], there is no evidence that
S100A1 and/or S100B can act as substitutes for
S100A10.
Analogously, since phosphorylation of annexin I
results in an enhancement of its phospholipid-bind-
ing activity [129], S100A11, which binds to and in-
hibits annexin I phosphorylation [86,95] (Table 1),
might likewise regulate annexin I association with
membranes and other targets (also see Section 3.1.4).
S100A4 inhibits the PKC-dependent phosphoryla-
tion of myosin heavy chain [130] thereby putatively
modulating the cytoskeleton dynamics in metastatic
cells (Table 1) (see Section 5).
The ability of several S100 proteins to regulate the
phosphorylation state of a number of kinase sub-
strates suggests that these proteins have a role in
signal transduction, particularly by linking elevation
of the cytosolic Ca2 concentration to the phospho-
rylation state of the above mentioned S100 target
proteins. Further supporting this possibility is the
recent ¢nding that S100B is induced in rat myocar-
dium post-infarction concomitantly with the down-
regulation of a fetal protein, skeletal K-actin, and
that transfection of an S100B expression vector
into cultured neonatal rat cardiomyocytes inhibits
the L-PKC-mediated induction of skeletal K-actin
and embryonic L-myosin heavy chain, another fetal
protein, by norepineprine and phenylephrine [131].
These data suggest that S100B might act as a nega-
tive regulatory element that limits the hypertrophic
response following myocardial infarction via inhibi-
tion of a L-PKC-dependent phosphorylation of an
unknown factor [131]. It is interesting to note that
S100A1 and S100B bind to the basic helix-loop-helix
(bHLH) sequence found in the transcription factors
MyoD and E12 [111,132] and that at least S100A1
inhibits MyoD phosphorylation [111] (Table 1).
Binding of S100A1 and S100B to the bHLH se-
quence in MyoD is regulated by N-terminal MyoD
sequences, which apparently render the bHLH motif
unaccessible to S100A1 and S100B (and calmodulin)
[132]. On this basis, S100A1 and S100B might have a
role in the regulation of the activity of certain tran-
scription factors (Table 1). It is not known at present
whether the factor suggested to be inhibited by
S100B in myocardium post-infarction [131] is the tis-
sue-speci¢c MyoD or some other transcription fac-
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tor. Also unknown is the role, if any, of S100A1 in
the regulation of hypertrophic response to and the
sequence of events leading to expression of S100B in
myocardium post-infarction.
The ability of some S100 proteins to inhibit pro-
tein phosphorylation by interacting with kinase sub-
strates rather than with kinases could represent a
means to ¢nely regulate speci¢c steps of those signal-
ling pathways in which phosphorylatable S100 target
proteins have a role.
3.1.2. Regulation of enzyme activity
No enzymatic activity has been ascribed to any
member of the S100 family thus far. By contrast,
several S100 proteins have been shown to regulate
some enzyme activities. S100A1 and S100B were
shown to interact with a brain fructose-1,6-bisphos-
phate aldolase stimulating its Vmax [133], whereas
S100A1, but not S100B, was reported to bind to
and to inhibit glycogen phosphorylase [134] (Table
1). Also, S100A1 inhibits and S100B stimulates phos-
phoglucomutase [135] (Table 1). These ¢ndings sug-
gest that S100A1 and S100B might have a role in the
regulation of energy metabolism. The ¢nding that
S100A1 is abundantly expressed in slow-twitch skel-
etal muscle cells and cardiomyocytes [1^3] has been
put in relation to a possible role of this protein in
preventing fatiguability of slow-twitch skeletal
muscle cells by reducing glycogen breakdown [135].
Recently, S100A1 and, to a much smaller extent,
S100B were shown to interact with and to stimulate
the sarcomeric, myosin-associated giant kinase
twitchin in a Ca2- and Zn2-dependent manner
[136] (Table 1). S100A6 and calmodulin, though
able to interact with twitchin, do not activate its
kinase activity [137]. The ability of S100A1 to regu-
late the twitchin kinase activity appears relevant in
consideration of the abundance of S100A1 in striated
muscle cells and its localization near the Z discs
([138,139], and unpublished observations) to which
twitchin is also linked. As the S100A1-binding site
on twitchin has been identi¢ed [136], the regulatory
activity of S100A1 on this kind of kinase might be of
physiological relevance. Yet, the available genomic
databases indicate that invertebrates do not express
S100 proteins and, accordingly, attempts to identify
S100A1 or its mRNA in the nematode C. elegans
proved unsuccessful (M. Garbuglia and R. Donato,
unpublished observations). Twitchin is a member of
a family of giant protein kinases involved in the reg-
ulation of muscle contraction and the mechanoelastic
properties of the sarcomere in invertebrates
[140,141]. The corresponding vertebrate protein is
titin [140,141], to which S100A1 also binds (M. Gar-
buglia and R. Donato, unpublished observations).
Aside from regulatory e¡ects of S100A1 on twitch-
in/titin kinase activity, which could be relevant to the
general economy of muscle contraction, the interac-
tion of S100A1 with members of this sarcomeric pro-
tein family might be important in the context of the
role of twitchin/titin as the molecular entity respon-
sible for the mechanoelastic properties of skeletal
muscles [140,141]. Conclusions in this respect must
await information about S100A1-dependent regula-
tion of titin kinase activity and/or titin-based mecha-
noelastic properties of vertebrate skeletal muscles as
well as clear evidence of localization and/or Ca2-
dependent translocation of S100A1 to the center
part of the sarcomere where the catalytic domain
of twitchin/titin is located [140,141].
S100B and, to a smaller extent, S100A1 stimulate
Ndr, a nuclear serine/threonine protein kinase impor-
tant in the regulation of cell division and cell mor-
phology, in a Ca2-dependent manner [142] (Table
1). S100B interacts with a basic/hydrophobic motif
within the N-terminal regulatory domain of Ndr, and
S100B binding can be inhibited by a synthetic pep-
tide derived from this Ndr region [142]. Since S100B
has been implicated in the regulation of cell cycle (see
Section 4), the S100B/Ndr interactions could be of
physiological relevance.
S100A1 and S100B were reported to regulate the
adenylate cyclase activity [143,144], apparently via an
interaction with a G-protein [145] (Table 1). Further
analysis is required to draw de¢nite conclusions
about the physiological relevance of these observa-
tions.
Stimulation of a membrane-bound guanylate cy-
clase activity in photoreceptor outer segments by
S100A1 and S100B in the presence of micromolar
levels of free Ca2 in vitro was also reported [146^
148] and S100B was shown to be identical to and
interconvertible with CD-GCAP (calcium-dependent
guanylate cyclase-activating protein) [148] (Table 1).
It is known that activation of photoreceptor outer
segment membrane-bound guanylate cyclase has an
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important role in phototransduction, serving to in-
crease the range of intensities to which the rod can
respond, and that several Ca2-binding proteins are
implicated in phototransduction [149,150]. S100A1-
and S100B-stimulated membrane-bound guanylate
cyclase was localized to photoreceptor disc mem-
branes, photoreceptor cell bodies, and retinal Mu«ller
cells, by ultracytochemistry [151]. Activation of this
enzyme by either S100 protein in the outer segment
of photoreceptors proved dependent on Ca2 (with
much smaller free Ca2 concentrations required in
the case of S100B than S100A1) and the dark
[146,147,151]. In contrast, S100A1/B-dependent acti-
vation of membrane-bound guanylate cyclase activity
in photoreceptor cell bodies and retinal Mu«ller cells
was dependent on Ca2 and independent of light- or
dark-adaptation [151]. The possibility that S100A1
and S100B might have a role in the regulation of
membrane-bound guanylate cyclase activity is sup-
ported by the ¢nding that both proteins are present
in the outer segments of photoreceptors and are co-
localized with that enzyme to disc membranes [151].
Interestingly, the membrane-bound guanylate cyclase
activity stimulated by either S100 protein is insensi-
tive to the natriuretic peptides, which activate anoth-
er member of the membrane-bound guanylate cyclase
family in other retinal cells [150]. These data suggest
that S100B and, eventually, S100A1 might play a
role in dark-adaptation of photoreceptors in verte-
brates or, alternatively, S100A1 and S100B may
transduce a di¡erent kind of signal in photoreceptors
and Mu«ller cells via stimulation of a membrane-
bound guanylate cyclase. As mentioned above, the
hinge region and the C-terminal extension have
been implicated in the recognition of membrane-
bound guanylate cyclase by S100B [78].
The S100A8/S100A9 heterodimer inhibits casein
kinase I and II, two enzymes that phosphorylate
topoisomerase I and RNA polymerases I and II
[152] (Table 1). These ¢ndings suggest that S100A8
and S100A9 and/or the S100A8/S100A9 heterodimer
might regulate myeloid cell maturation and function.
It is important to note that S100A8 and S100A9
expression in monocytes occurs in early stages of
di¡erentiation [153] and in in¢ltrating monocytes,
but not in resident tissue macrophages [154]. This
suggests that the expression of S100A8 and
S100A9, formation of the S100A8/S100A9 complex,
and S100A8/S100A9-dependent regulation of casein
kinase I and II activity are related to a de¢nite func-
tional stage of macrophages and participate in the
in£ammatory response (see Section 3.2.4).
S100A10 interacts with cytosolic (85-kDa) phos-
pholipase A2 and inhibits its activity [155] (Table
1). Interaction occurs at the C-terminal region of
the enzyme and the inhibitory e¡ect is independent
of the presence or absence of the natural S100A10
ligand, annexin II, suggesting that the phospolipase
A2 site might not comprise the S100A10 C-terminal
extension. Inhibition of cytosolic phospholipase A2
activity by S100A10 appears of physiological impor-
tance since S100A10 associates with this enzyme in
vivo, the formation of the S100A10/phospholipase
A2 complex results in a decreased release of archi-
donic acid, and antisense inhibition of S100A10 ex-
pression results in an increased phospholipase A2
activity and a parallel increase in arachidonic acid
release by cultured cells [155]. These data point to
a role of S100A10 in the in£ammatory response;
speci¢cally, they point to an anti-in£ammatory role
of this protein.
With the exception of membrane-bound guanylate
cyclase [78], there is no information at present about
the location of the site(s) on S100 proteins that rec-
ognize(s) the above enzyme or enzyme regulatory
proteins.
3.1.3. Regulation of Ca2+ homeostasis
S100A1 is localized to triades in striated muscle
cells [139] and stimulates Ca2-induced Ca2 release
in skeletal muscle cells [156] (Table 1). A similar
stimulatory e¡ect was reported for a mixture of
S100A1 and S100B consisting of V20% S100A1
and V80% S100B [157]. These latter studies also
showed that the S100A1/B mixture blocks the inhib-
itory e¡ect of ruthenium red on Ca2-induced Ca2
release and increases the binding a⁄nity of ryano-
dine for its receptor, suggesting a direct binding of
these proteins to the ryanodine receptor [157]. Con-
sistently, direct S100A1 binding to the ryanodine re-
ceptor, the molecular entity responsible for Ca2-in-
duced Ca2 release, has been recently documented
[158] (Table 1). S100A1, which binds to puri¢ed rya-
nodine receptor at both nanomolar and micromolar
Ca2 levels, increases the a⁄nity of ryanodine bind-
ing to its receptor at nanomolar Ca2 concentrations
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and, under these conditions, increases the open prob-
ability of the ryanodine receptor channel [158]. Bind-
ing of S100A1 to the ryanodine receptor has been
mapped to residues 1861^2155, 3774^3874, and
4425^4621, although with di¡erent Ca2 require-
ments [158]. The ryanodine receptor polypeptide de-
¢ned by residues 4425^4621, which binds S100A1 at
nanomolar Ca2 concentrations, but much less so at
millimolar Ca2 concentrations, and binds calmodu-
lin with a low a⁄nity, has been implicated in the
Ca2-dependent regulation of the Ca2 release chan-
nel (see [158] for literature). Together, these data
strongly suggest the possibility that S100A1 has a
role in intracellular Ca2 homeostasis in skeletal
muscle cells by directly activating the ryanodine re-
ceptor. In this context, it is interesting to note that
S100A1 is down-regulated in failing human heart
[159], a ¢nding that has been put in relation to a
reduced Ca2-induced Ca2 release from sarcoplas-
mic reticulum in heart failure [159]. The S100A1 re-
gion implicated in the binding of the ryanodine re-
ceptor is not known at present.
3.1.4. Regulation of the dynamics of cytoskeleton
components
All three major constituents of cytoplasmic cyto-
skeleton, i.e. MTs, IFs and micro¢laments (MFs),
and tropomyosin and myosin appear to be targets
of S100 proteins. S100A1 and S100B have been re-
ported to inhibit MT protein and puri¢ed tubulin
assemblies in the presence of micromolar concentra-
tions of free Ca2 and to increase the Ca2 sensitivity
of preformed MTs, in a pH-dependent manner in
vitro [120^123,160^162] (Table 1). In particular,
S100A1 and S100B cause a strikingly fast disassem-
bly of preformed MTs in the presence of Ca2 and
thus could be two of the factors responsible for the
so-called Ca2-induced catastrophic MT disassembly
([163] and references therein). Immunocytochemical
analyses have documented the association of S100B
with axonemal MTs, centrioles, basal bodies, the mi-
totic spindle, the centrosomes, and the center part of
the midbody in telophase cells (the centrosomes and
the center part of the midbody are MT nucleation
centers [164,165]) as well as with cytoplasmic MTs
[1,2,38,166], observations that support the idea that
S100B might have a role in avoiding excess tubulin
polymerization, in the regulation of tubulin-depend-
ent stimulation of the ATPase activity associated
with MAPs (the MT-associated proteins) [167], in
remodelling of MTs at sites where the free Ca2 con-
centration is expected to be relatively high, e.g. the
cytoplasm facing plasma membranes and membranes
of Ca2 stores [168,169], or in the modulation of
tubulin-dependent regulation of signalling pathways
[170]. Together with the observation that a fraction
of S100B exists in a membrane-bound state [37], and
interacts with arti¢cial membranes [171], e¡ects of
S100B on the MT dynamics might be relevant in
the regulation of MT-endosome interactions, which
are considered important in the mechanism of fusion
of endosomes [172], transport from early endosomes
to late endosomes [173], and apical recycling [174]. In
this regard, it is interesting to note that S100B was
also localized to Golgi membranes and other perinu-
clear membranes by immunocytochemistry [38,166,
175]. The presence of S100B at MT nucleation cen-
ters (the centrosomes and the center part of the mid-
body in dividing cells) supports the possibility that
S100B regulates the nucleation of MTs. Actually,
S100A1 and S100B inhibit MT assembly by interfer-
ing with both the nucleation and the elongation of
MTs in vitro [120,176]. In contrast, in spite of its in
vitro e¡ects, S100A1 seems not to be localized to
MTs or MT nucleation centers ([166,177], and un-
published observations), suggesting that this protein
might intervene in the regulation of MT dynamics by
interacting with unassembled tubulin. Interestingly,
recent evidence suggests that inhibition of S100A1
synthesis in PC12 cells results in an increase in tubu-
lin levels and the number of neurites extended in
response to NGF, and a decrease in cell proliferation
[178] (Table 1). The increase in tubulin levels is due
to an increase in unpolymerized tubulin at constant
levels of polymerized tubulin [178], which appears in
line with the ¢nding that S100A1 inhibits tubulin
assembly [120^122]. The observed decrease in prolif-
eration of S100A13 PC12 cells is suggested to depend
on lack of e¡ects of S100A1 on growth regulatory
factors [178], the identity of which remains to be es-
tablished. As mentioned above, S100A1 interacts with
certain transcription factors thereby blocking their
interaction with DNA [111,132]: absence of S100A1
might result in deregulation of the gene program
underlying PC12 cell proliferation and activation of
gene program(s) implicated in cell di¡erentiation.
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Direct binding of S100A1 and S100B to desmin
and GFAP, two proteins that self-assemble to form
the type III IFs speci¢c to muscle and glial cells,
respectively, results in a dose-dependent inhibition
of desmin and GFAP assemblies and stimulation of
desmin and GFAP IF disassembly, in the presence of
a few micromolar free Ca2 levels [83,84,179] (Table
1). The S100 protein e¡ect is stoichiometric (1 mol of
desmin or GFAP/mol of S100A1 or B monomer with
an a⁄nity of 0.5^1 WM), resulting in inhibition of
nucleation and elongation of desmin and GFAP
IFs, as well as in stimulation of the polymerized-un-
polymerized desmin and GFAP exchange [83^85,179]
(Fig. 2). Other S100 proteins (S100A6 and S100A10)
do not bind to desmin or a¡ect desmin or GFAP
assembly [83,126]. The inhibitory e¡ects of S100A1
and S100B on desmin and GFAP assemblies can be
blocked by annexin VI via annexin VI binding to
either S100 protein [96]. Annexin V, which also in-
teracts with S100A1 and S100B, has no e¡ects on the
above S100 e¡ects on IF formation [96]. S100A1 and
S100B bind to a stretch of residues found in the
GFAP and desmin N-terminal domain which shares
a high sequence identity with the S100A1/S100B-in-
hibitory peptide TRTK-12 [85] and contains a motif,
the RP-box motif, shown to be important for the
formation of GFAP, desmin and vimentin IFs [180]
(Fig. 2). S100B has been localized to IFs in both
untreated cells and in Triton-cytoskeletons of cul-
tured Schwann cells, astrocytes, rat L6 myoblasts
and myotubes, and renal cells ([38,166,181], and un-
published observations). By similar approaches, in
mature skeletal muscle cells and in chick embryo
myotubes S100A1 has been localized to structures
associated with Z discs, the sarcolemma and the fas-
cia adherens of the intercalated discs, as well as to
the sarcoplasm facing the sarcolemma and the sarco-
plasmic reticulum ([138,139], and unpublished obser-
vations). However, whereas S100A1 appears to be
located close to sites where desmin IFs are also
found (e.g. the Z discs in mature striated muscle
cells), no association of this protein with IFs in rat
L6 myoblasts and myotubes could be documented
([166,177], and unpublished observations). This sug-
gests that S100A1 is closely located, but not linked to
IFs, and/or that S100A1 might intervene in the reg-
ulation of IF dynamics by interacting with unas-
sembled subunits, as it seems to be the case with
tubulin. Altogether, these observations suggest that
S100A1 and S100B could have a role in the regula-
tion of the state of assembly of type III IFs, albeit
with di¡erent mechanisms of action. On the one
hand, S100A1 and S100B might be important in
avoiding excess IF assembly and contributing to
the appropriate orientation of IFs, and, on the other
hand, they might participate in remodelling IFs in
mitosis, cell locomotion and shape change (e.g. in
development), and eventually, in skeletal muscle
Fig. 2. Schematic representation of the Ca2-dependent interac-
tion between S100A12 or S100B2 dimers and desmin or GFAP
tetramers. A pair of S1002 dimers crossbridges two desmin or
GFAP dimers by interacting with the desmin or GFAP N-ter-
minal domain [85,196]. Binding of either S100 protein to the N-
terminal domain results in inhibition of desmin or GFAP as-
sembly into type III intermediate ¢laments. Formation of mac-
rocomplexes composed of four desmin or GFAP subunits plus
four copies of S100A1 or S100B monomers was observed by
chemical crosslinking [85,195]. A similar mode of interaction,
i.e. crossbridging of two homologous or heterologous target
proteins by an S100 dimer, could apply to most, if not all,
S100-target protein complexes that form in a Ca2-dependent
manner (see text). An analogous mode of interaction could ap-
ply to those S100-target protein complexes that form in a
Ca2-independent manner (see Fig. 7 in [39]).
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cells, during the cycle of contraction-relaxation. In-
terestingly, astrocytes in the brain of mutant mice
expressing a much reduced amount of S100B exhibit
larger amounts of GFAP IFs [182], a ¢nding that has
been put in relation [182] to the ability of S100B to
inhibit GFAP IF assembly.
As mentioned above, three large molecular weight
proteins, pro¢laggrin and trichohyalin and repetin,
that are expressed in keratinocytes and are involved
in the lateral association of keratin IFs in di¡erenti-
ated epithelial cells, contain a long stretch of residues
highly homologous to S100 proteins [24^27] (Table
1). Since S100A1 and S100B are also expressed in a
restricted number of epithelial cells [183] and
S100A7, S100A8, S100A9 and S100A10 are also ex-
pressed in some epithelial cells [3], it would be of
interest to see whether these proteins are also in-
volved in the regulation of keratin IFs (type I and
II IFs).
S100A10 is the natural ligand of annexin II with
which it forms an annexin II2-S100A102 heterote-
tramer [31^33,36]. Binding of S100A10 to annexin
II targets annexin II to the cortical cytoskeleton of
¢broblasts and adrenal chroma⁄n cells [184^186],
besides remarkably reducing the Ca2 requirement
for phospholipid binding and chroma⁄n granule ag-
gregation and fusion by annexin II [187^189], and
favors the annexin II-dependent bundling of F-actin
[31,190,191] (Table 1). The F-actin-binding site on
annexin II is located in the annexin II core domain
[31,190]. While the F-actin-bundling activity of the
annexin II2-S100A102 heterotetramer might be re-
lated to the reorganization of F-actin in exocytosis
[34,35,117,188,191^193], some uncertainty exists as
to the physiological relevance of this annexin II2-
S100A102 heterotetramer activity because annexin
II does not colocalize with stress ¢bres [194] and
the annexin II2-S100A102 heterotetramer and F-actin
are coexpressed in several other cell types not char-
acterized by exocytotic events [35]. Yet, the fact that
S100A10 induces a redistribution of annexin II with-
in cells [184^186] and inhibits annexin II phospho-
rylation [114^116] strongly suggests that this protein
regulates annexin II activities, including annexin II
association with cytoskeleton constituents. More-
over, the annexin II2-S100A102 heterotetramer might
be implicated in docking F-actin to plasma mem-
branes (see below). The annexin II2-S100A102 heter-
otetramer binds to both unassembled and assembled
GFAP in the presence of Ca2 [195] and rescues the
ability of GFAP to assemble into typical IFs under
conditions in which assembly is inhibited (e.g. at
pHs 6.7) [126,127] (Table 1). While the annexin II
moiety is the molecular entity responsible for these
e¡ects, the integrity of the annexin II2-S100A102 het-
erotetramer is required for optimal e¡ects [126], in-
dicating that S100A10 binding to annexin II is a
prerequisite for annexin II-GFAP interactions. The
annexin II2-S100A102 heterotetramer interacts with
the GFAP rod domain [196], which is critical for
the formation of dimers/tetramers of IF subunits
[197,198], whereas the GFAP-binding site on annexin
II is tentatively located at the transition between the
annexin II N-terminal tail and domain I of the an-
nexin II core [126]. The stimulatory e¡ect of the an-
nexin II2-S100A102 heterotetramer on GFAP assem-
bly is counteracted by S100A1/B, the inhibitory e¡ect
of which is in turn counteracted by the annexin II2-
S100A102 heterotetramer [127]. The opposite e¡ects
of S100A1/B and the annexin II2-S100A102 heterote-
tramer appear to depend on the di¡erent location of
the S100A1/S100B and the annexin II2-S100A102
heterotetramer sites on GFAP [85,196]. Whether or
not the annexin II2-S100A102 heterotetramer associ-
ates with GFAP IFs in vivo is not known at present.
S100A10 has been identi¢ed as one precursor of the
corni¢ed envelope of cultured epidermal keratino-
cytes [199]. Interestingly, annexin II was not found
associated with S100A10 in that structure, and this
represents one of the rare examples of presence of
S100A10 on a cell structure without its accompany-
ing protein, annexin II. It is suggested that annexin
II, by virtue of its membrane phospholipid-binding
property, might target S100A10 to the corni¢ed en-
velope (a crosslinked sheath of protein that forms
beneath the plasma membrane during the ¢nal stages
of epidermal keratinocyte di¡erentiation), and de-
taches from S100A10 during envelope assembly
[199]. While the identity of S100A10 target protein(s)
in the corni¢ed envelope is not known, one or more
of the proteins detected in the corni¢ed envelope
might be a target protein for S100A10. If so, given
the mode of assembly of S100A10 and annexin II
into the annexin II2-S100A102 heterotetramer [31^
33,36,200], one might speculate that the S100A102
dimer interacts with its target protein(s) in the enve-
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lope, while still bound to annexin II, through a site
that does not comprise the S100A10 C-terminal ex-
tension, and that annexin II detaches from S100A10
because of that interaction. This scenario di¡ers sub-
stantially from that proposed for translocation of the
annexin II2-S100A102 heterotetramer to membranes
[186] and stimulation of GFAP assembly [126]. Com-
plex formation between S100A10 and annexin II is
required for the Ca2-dependent association of an-
nexin II with membranes [184^189] where the annex-
in II2-S100A102 heterotetramer could mediate the
association of F-actin with the membrane lipid bi-
layer and/or membrane-membrane associations that
precede the actual membrane fusion [189,201,202].
Also, annexin II needs to be associated with
S100A10 for maximal stimulatory e¡ect of GFAP
assembly [126].
S100A11 also has been identi¢ed as one compo-
nent of the corni¢ed envelope of cultured epidermal
keratinocytes where it is likely bound to annexin I
[199] (Table 1). S100A11 is suggested to be targeted
by annexin I to the keratinocyte plasma membrane
in a Ca2-dependent manner and thus made avail-
able for crosslinking [199]. S100A11 dimers, trimers,
tetramers and larger multimers can be generated in
vitro upon treatment with a transglutaminase and
similar S100A11 oligomers can be extracted from
the corni¢ed envelope of cultured epidermal kerati-
nocytes, pointing to in vivo occurrence of S100A11
oligomerization [203]. It is suggested that transgluta-
minase crosslinks S100A11 to the N-terminal domain
of annexin I in the presence of Ca2 [203]. Targeting
of S100A11 to endosomes by annexin I has also been
reported [204]. However, it not clear whether annexin
I-dependent translocation of S100A11 to the kerati-
nocyte corni¢ed envelope and/or endosomes serves to
anchor S100A11 to speci¢c membrane sites where
this protein regulates cytoskeleton constituents, or
this event is unrelated to the organization of the
membrane skeleton. Also, it is not clear how the
proposed transglutaminase-dependent crosslinking
of S100A11 to annexin I [203] results in the forma-
tion of S100A11 oligomers within the corni¢ed enve-
lope. Overall, there is no information about the func-
tional role of S100A11 dimers/oligomers within the
keratinocyte corni¢ed envelope. The annexin I2-
S100A112 heterotetramer has been suggested to serve
to interconnect membranes of di¡erent endosomal
compartments, i.e. to hold endosomal membranes
in place for their actual fusion and/or to organize
the endosomal compartment [204] (Table 1). The
available evidence suggests that S100A11 forms an-
nexin I2-S100A112 heterotetramers in a Ca2-de-
pendent manner, in which the S100A112 dimer binds
a copy of annexin I on opposite sides [86,95]. As the
S100A112 dimer is a stable structure and S100A11
binding to annexin I depends on Ca2, S100A11
would be kept onto membranes as long as the
Ca2 concentration remains relatively high, with de-
tachment of the whole S100A112 dimer from annexin
I and, hence, membranes upon decrease in the Ca2
concentration. Thus, S100A11 would serve to render
the annexin I activity as a membrane crossbridging
agent possible, in a Ca2-regulated manner.
S100A8, S100A9, and S100A12, which is an
S100A9 isoform that lacks the ¢rst four amino acids
and is the product of an alternative translation of a
single mRNA species [41,205^210], translocate to
plasma membranes and vimentin IFs in monocytes
and granulocytes upon elevation of cytosolic Ca2
concentration [207,209] (Table 1). Also, S100A8
and S100A9 translocate to keratin IFs upon eleva-
tion of the free Ca2 concentration in epithelial cells
[211]. Phosphorylation of S100A9 and S100A12 in-
creases the extent of this translocation as well as the
Ca2-binding a⁄nity of these proteins, and translo-
cation of S100A8 to membranes and cytoskeleton
depends on prior complexation with S100A9
[209,212]. PKC-independent and PKC-dependent
phosphorylation of S100A8 was reported [212]. Par-
ticularly, PKC-dependent phosphorylation of
S100A8 is suggested to play a modulatory role in
the translocation of this protein to membranes dur-
ing neutrophil activation [213]. Phosphorylated
S100A8 and S100A9 display increased a⁄nity for
Ca2. Translocation of S100A8/S100A9 to plasma
membranes and cytoskeleton might be put in relation
to the roles of plasma membranes and the cytoskel-
eton in migration, chemotaxis, degranulation, phag-
ocytosis and respiratory burst, all of which are char-
acteristic of activated granulocytes and monocytes.
Accordingly, complex formation between S100A8
and S100A9, which appears essential for these pro-
teins to take part in the general process of granulo-
cyte and monocyte activation, occurs in a subpopu-
lation of activated macrophages during e.g. allograft
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rejection, despite individual proteins are being ex-
pressed in all monocytes under these conditions
[214]. Thus, occurrence or non-occurrence of
S100A8/S100A9 complex appears to re£ect distinct
functional stages of macrophages with special refer-
ence to the mode S100A8/S100A9 transduces the
Ca2 signal during the various steps of the in£am-
matory response (also see Section 3.2.4). S100A8 and
S100A9 are also expressed in resident, activated mi-
croglial cells in brain in£ammatory processes and
Alzheimer’s disease [215], as well as in ischemic brain
lesions [216]. In the latter case, expression of these
proteins in microglial cells is restricted to the ¢rst
three days post infarction, pointing to a speci¢c
role of S100A8 and S100A9 during the early phase
of tissue reaction. While it is suggested that the
S100A8/S100A9 complex modulates Ca2-dependent
interactions between IFs and membranes [207,209],
there is no information as to whether or not
S100A8 and/or S100A9 a¡ect IF dynamics and IF
interactions with membranes and/or other cytoskele-
ton components. Also, the functional implications of
these interactions are still to be elucidated. Recently,
activation of PKC in monocytes has been shown to
result in translocation of the S100A8/S100A9 com-
plex to MTs [61]. See below for implications of se-
creted S100A8/S100A9 as well as the S100A8-like
protein, CP-10, in the in£ammatory response.
S100A1/B binds to the actin-associated proteins,
caldesmon and calponin [110,124,125,217^219] (Ta-
ble 1). Binding of S100A1/B to caldesmon reverses
the caldesmon inhibitory e¡ect on actomyosin ATP-
ase activity [110,124,217]. Interaction occurs with a
stretch of residues (residues 669^737) located in the
C-terminal domain of caldesmon [217], which is sug-
gested to contain a sequence around W-692 similar
to the consensus sequence found in CapZK from
which the S100A1- and S100B-inhibitory peptide,
TRTK-12 was derived [71,72]. This observation fur-
ther supports the possibility that S100A1/B recog-
nizes and regulates target proteins exhibiting the con-
sensus sequence (K/R)(L/I)XWXXIL. The list of
these target proteins includes CapZK, GFAP, desmin
(and, likely, vimentin), p53, neuromodulin, neurogra-
nin, and caldesmon, thus far (see Section 2.2 and
Table 1). Similarly, S100B binding to the N-terminal
22-kDa fragment of calponin relieves the calponin-
dependent inhibition of actomyosin ATPase activity
[217].
A number of S100 proteins interact with tropo-
myosin and muscle and non-muscle myosin.
S100A4 interacts with muscle and non-muscle myo-
sin heavy chain [220^225] (Table 1). S100A4 binds to
non-muscle tropomyosin in NIH 3T3 cells and is
found associated with this cytoskeleton protein in
MF bundles [222]. Binding of S100A4 to MFs and
colocalization of S100A4 with MFs in other cell
types were also reported [222,225,226]. Binding of
S100A4 was reported to occur to the region in tro-
pomyosin containing residues 39^107 [222] (Table 1).
It is suggested that binding of S100A4 might confer
Ca2 sensitivity to tropomyosin regulation of acto-
myosin ATPase activity [222]. Recently, S100A4 has
been reported to inhibit PKC-dependent phospho-
rylation of myosin heavy chain at S-1917, a residue
that is found in a C-terminal stretch of myosin res-
idues (residues 1909^1937) to which S100A4 binds
[130]. It is suggested that S100A4 might play a role
in the dynamics of myosin ¢laments (which in turn
depends on the phosphorylation state of this cyto-
skeleton molecule) and, hence, in metastatic invasive-
ness [130] (see Section 5). S100A6 binds to muscle
tropomyosin in vitro [56], but no functional corre-
lates of this interactions have been reported. Instead,
as with S100A1/B, binding of S100A6 to caldesmon
reverses the inhibitory e¡ect of caldesmon on acto-
myosin ATPase activity [227]. It is not known
whether S100A6 associates with caldesmon in vivo
or S100A6 and S100A1/B share the binding site on
caldesmon. S100A2 binds to tropomyosin with a 1:1
stoichiometry in an epithelial cell line and undergoes
redistribution upon di¡erentiation of these cells [103]
(Table 1). In particular, S100A2 appears to translo-
cate from the cytoplasm to microvilli, where it coloc-
alizes with MFs, in cells induced to di¡erentiate from
a ¢broblast phenotype to an epithelial phenotype.
However, S100A2 does not colocalize with tropo-
myosin in these cells. It is suggested that S100A2
might be important to prevent association of tropo-
myosin to MFs in microvilli (which in fact lack tro-
pomyosin) and, thus, to play a role in the organiza-
tion of the actin cytoskeleton via its interaction with
tropomyosin. In support of this possibility is the
¢nding that in vivo association of S100A2 with tro-
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pomyosin is transient and depends on elevation of
cytosolic Ca2 [103].
Thus far, three observations suggest that S100B
and/or S100A1 proteins could play a role in the reg-
ulation of the state of assembly of MFs. (i) C6 glio-
ma cells in which the expression of S100B had been
selectively inhibited by antisense oligonucleotide
techniques, were observed to display a more organ-
ized MF network [228], suggesting an inhibitory ef-
fect of S100B on MF formation. However, there is
no evidence presented of association of S100B with
G-actin or F-actin or of e¡ects of S100B on actin
assembly. Since S100B3 C6 cells divide at reduced
rate as compared to the S100B counterpart, it is
possible that the more organized MF network found
in S100B3 cells results from a less undi¡erentiated
state of the latter cells [228]. (ii) Recently, the K-sub-
unit of the actin capping protein, CapZ (a 35-kDa
protein that associates with CapZL, a 32-kDa pro-
tein, to form a dimer that caps F-actin and acts as a
nucleation center for MFs [229^232]), was identi¢ed
as a target of S100B and S100A1 [71,72] (Table 1).
The identi¢cation of CapZK as an S100A1/B-binding
protein was obtained through the previous isolation
by Ca2-dependent a⁄nity chromatography on
S100B-Sepharose of a subfamily of peptides display-
ing sequence identity to a consensus sequence con-
tained in the C-terminal half of CapZK [71]. In ad-
dition to direct binding of S100A1/B to CapZK (Kd
in the nanomolar range in the presence of submilli-
molar Ca2 concentrations), a synthetic peptide,
TRTK-12, obtained from the consensus sequence
found in CapZK, was shown to bind to S100A1
and S100B with a stoichiometry of 1 mol of pep-
tide/mol of S100A1 or B monomer and to inhibit
the interaction of S100A1 and S100B with CapZK
in a dose-dependent manner and stoichiometrically
[71,72]. These observations suggest that CapZK
might be regarded as a physiological target of
S100A1 and S100B and, hence, that S100A1 and
S100B might be involved in the regulation of the
state of assembly of MFs by interacting with CapZK.
At present, however, experimental data on functional
implications of the S100A1/B-CapZK interactions are
lacking and no information is available about coloc-
alization of S100A1/B with CapZ. The above obser-
vations also suggest that the synthetic peptide,
TRTK-12, might represent a powerful tool for ana-
lyzing several aspects of the functional implications
of S100A1 and S100B. Also, TRTK-12 might be
used in studies aimed at identifying the structure of
the site(s) on S100A1/B that mediate the interaction
of these proteins with their target proteins. As men-
tioned above, the C-terminal extension of S100A1
was implicated in the recognition of TRTK-12
[70,79] and use of TRTK-12, which inhibits the in-
teraction of S100A1 and S100B protein with GFAP
and desmin and blocks the ability of S100A1 and
S100B to inhibit GFAP and desmin assemblies into
IFs in vitro [85], permitted the identi¢cation of the
putative S100A1- and S100B-binding site on GFAP
and desmin [85]. (iii) S100A1 was reported to bind
Ca2-dependently to F-actin in vitro and to trans-
locate to stress ¢bres upon elevation of cytosolic
Ca2 concentration in cultured smooth muscle cells
[226]. The functional correlates of this interaction are
not known at present.
All the above observations strongly suggest that
one general role of S100 proteins is to regulate cell
morphology, the dynamics of certain cytoskeleton
constituents, and the reciprocal relationships of cy-
toskeleton elements via their direct and/or indirect
interactions with MTs, IFs, MFs, myosin, and/or
tropomyosin. The dimeric structure of S100 proteins
renders these proteins potential candidates to cross-
bridge individual cytoskeleton components to each
other and/or to membranes, and/or to anchor some
enzymes (aldolase, glyceraldehyde-3-phosphate dehy-
drogenase, and phosphoglucomutase), shown to be
S100 target proteins [82,133,135], to the cytoskeleton.
See Section 5 for possible implications of S100A4
interaction with MFs, myosin and tropomyosin in
cancer.
3.2. Extracellular activities of S100 proteins
3.2.1. Neurotrophic e¡ects of the S100B disul¢de
crosslinked dimer
S100B is secreted by glial [57,58] and pituitary fol-
liculostellate [233] cells, and adipocytes treated with
stimulators of lipolysis [234,235]. Secretion of S100B
by glial cells has attracted much attention in view of
possible extracellular e¡ects of this protein in the
nervous system. Indeed, a protein factor with ability
to promote neurite extension was identi¢ed as a di-
sul¢de crosslinked form of the S100B dimer [50], and
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S100B was shown to exert this e¡ect on speci¢c neu-
ronal populations [51,236^241] and to enhance sur-
vival of neurons during development [237^239] and
after injury [241] (Table 1). Also, S100B antisense
mRNA blocks the serotoninergic nerve sprouting in
the central nervous system induced by S100B [242].
Moreover, S100B prevents motor neuron degenera-
tion in newborn rats after sciatic nerve section [243]
and local administration of S100B stimulates regen-
eration of injured rat sciatic nerve [244], in vivo. All
these observations point to a physiological role of
secreted S100B as a neurotrophic factor, also in con-
sideration that this S100B activity occurs at nano-
molar concentration of the protein. In addition to
a paracrine e¡ect of (glial) S100B on neurons, which,
as anticipated, could be important during both devel-
opment and nerve regeneration, S100B appears to
exert an autocrine e¡ect on astrocytes, since the pro-
tein stimulates glial proliferation in vitro with con-
comitant expression of growth-associated proto-on-
cogenes [245] (Fig. 3). However, little is known about
the mechanisms through which S100B is secreted and
exerts its e¡ects on responsive cells. S100B lacks a
signal peptide sequence and is suspected to be re-
leased from glial cells via a mechanism similar to
that whereby other factors (e.g. ¢broblast growth
factors, ciliary neurotrophic factor, interleukins-1K
and 1L, and human endothelial growth factor) are
secreted or released [52]. The formation of the disul-
¢de crosslinked S100B dimer is accelerated by the
presence of high Ca2 and lipids [52]. It is known
that S100B interacts with lipids in the presence of
Ca2 and changes the structural properties of lipid
bilayers [171]. Thus, disul¢de crosslinked S100B
Fig. 3. Schematic representation of putative receptors for S100B, S100A8/S100A9, the S100A8-like CP-10 protein, S100A2, and
S100A7. Interaction of S100B with a putative receptor on responsive cells would cause a release of Ca2 from internal stores likely
via a phospholipase C (PLC)-dependent mechanism as well as up-regulation of proto-oncogenes [249], and NO production via induci-
ble nitric oxide synthase (iNOS) [270]. The signalling pathways activated by the S100A8/S100A9, the S100A8-like CP-10 protein,
S100A2, and S100A7 interaction with responsive cells are not known. Question points (?) denote absence of information about the ex-
istence and/or identity of receptors for any released S100 protein shown to a¡ect activities in target cells, and about the signalling
pathway(s) activated within responsive cells following S100 protein interaction. Grouping several S100 proteins acting on target cells
from outside is not to mean that released S100 proteins share a common plasma membrane receptor.
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dimers could form as a consequence of S100B-Ca2-
lipid interactions during the release process [52]. The
S100B/A1 heterodimer also interacts with Ca2 and
lipids [30], but is devoid of neurotrophic activity as
are other S100 family members. What seems to make
the di¡erence is the presence of two cysteine residues,
C-68 and C-84, which are speci¢c to S100B and are
essential for both the formation of S100B disul¢de
crosslinked dimers and S100B neurotrophic e¡ects
[51]. An important issue that remains to be eluci-
dated is represented by the molecular mechanism
underlying the S100B neurotrophic e¡ect and stimu-
latory e¡ect of glial proliferation. Thus far, no evi-
dence has been presented for the existence of an
S100B receptor on S100B target cells. However, cir-
cumstantial evidence suggests that S100B interacts
with speci¢c binding sites of protein nature on syn-
aptic plasma membranes [246^248]. Binding of
S100B to receptive cells results in an increase in the
intracellular free Ca2 concentration from internal
Ca2 stores via activation of phospholipase C and
the ensuing formation of IP3 [249] (Fig. 3). While
these observations suggest that the (yet undiscov-
ered) S100B receptor is linked to a de¢nite intracel-
lular signal pathway, it is not known how elevation
of cytosolic Ca2 transduces the S100B binding into
trophic e¡ects on responsive neurons and stimulation
of glia proliferation. Although, as anticipated, adipo-
cytes also release S100B [234,235], there is no infor-
mation about the functional meaning of this release.
Also, it is not known whether other S100B-express-
ing cells release the protein.
3.2.2. S100B in neurodegenerative disorders
While nanomolar concentrations of brain extracel-
lular S100B may be bene¢cial as outlined above, mi-
cromolar levels of the protein may have deleterious
e¡ects. For instance, high levels of S100B have been
detected in brains from patients with Down’s syn-
drome and with Alzheimer’s disease [250], the levels
of S100B are elevated in the activated astrocytes as-
sociated with amyloid-containing plaques in Alz-
heimer’s disease [251^253], and a progressive associ-
ation of both microglia overexpressing interleukin-1K
and astrocytes overexpressing S100B with d2 neuro-
¢brillary tangle stages has been documented [254].
Also, a selective up-regulation of S100B expression
has been detected in human temporal lobe epilepsy
[255] and increased expression of S100B and its
mRNA in rat and human brain occurs with age
[256,257]. These observations, together with the ¢nd-
ings that the human gene coding for S100B is located
on chromosome 21q22.3 [258] with consequent over-
dosage of S100B in Down’s syndrome, and that L-
amyloid stimulates the synthesis of both S100B
mRNA and S100B protein in C6 glioma cells and
primary astrocyte cultures [259], suggest that S100B
has a role in the pathogenesis of brain disorders as-
sociated with Alzheimer’s disease and Down’s syn-
drome. Probably, participation of S100B in the neu-
ropathological changes typical of Down’s syndrome
is a late event, since no signi¢cant di¡erences in the
accumulation of S100B mRNA and protein can be
detected during infancy in Down’s syndrome and
control subjects [260]. Also, whereas chronic eleva-
tion of S100B does not appear to be su⁄cient to
induce formation of L-amyloid plaques in the mouse
brain [261], L-amyloid precursor protein and its
mRNA were reported to increase in neuronal cul-
tures exposed to S100B [262]. On this basis, secreted
S100B is currently viewed as a cytokine which, like
interleukin-1 [263,264], promotes neuronal survival al
low concentrations but is neurotoxic at high levels.
As a cytokine, S100B would take part not only in the
pathophysiology of neurodegenerative disorders typ-
ical of Alzheimer’s disease and Down’s syndrome,
but also in brain in£ammatory diseases eventually
ending in Alzheimer-like disorders (see [265,266] for
reviews) (Table 1).
S100B would produce its neurotoxic e¡ects in vitro
by inducing apoptosis of both neuronal [267^269]
and glial cells [270,271] (Table 1). In one study, ex-
posure of PC12 neuronal cells to a mixture of brain
S100B/A1 caused a sustained elevation of cytosolic
Ca2 with concomitant appearance of apoptotic
bodies and DNA fragmentation typical of apoptosis
[267]. Elevation of cytosolic Ca2 was shown to de-
pend on a transmembrane capacitative £ux followed
by depletion of internal Ca2 stores [267]. This Ca2
increase could be blocked by nifedipine, a speci¢c L-
type Ca2 channel blocker, and completely abolished
by pretreatment of cells with thapsigargin, an inhib-
itor of endoplasmic reticulum Ca2-ATPase [267].
Also, nerve growth factor prevented the S100B/A1
toxic e¡ects on PC12 cells [268]. Toxic e¡ects of
S100B/A1 on neuronal cells were ascribed to binding
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of S100B/A1 to high a⁄nity sites on neuronal plasma
membranes [267]. In one other study, S100B was
shown to induce astrocyte apoptotic death by induc-
tion of the mRNA of inducible nitric oxide synthase
(iNOS) and elevation of this enzyme activity [270]
(Table 1 and Fig. 3). While S100B does not induce
the expression of iNOS in neurons, induction and
activation of this enzyme in astrocytes by exogenous
S100B would be responsible for the S100B toxic ef-
fects on neurons (and astrocytes) via di¡usion of NO
[269]. The ability of S100B to interact with the tumor
suppressor protein p53 and to block its thermal-de-
pendent oligomerization [88], and the recent observa-
tion that S100B cooperates with p53 to cause cell
growth arrest and apoptosis [271] have been sug-
gested to indicate a role of S100B in the regulation
of cell growth. However, by the same mechanism
overexpression of S100B and altered Ca2 homeo-
stasis might contribute to neurodegenerative disor-
ders [271]. Recent observations suggest that micro-
molar concentrations of (extracellular) S100B
activate cultured microglia cells (C. Adami, G. Sorci,
E. Blasi, F. Bistoni, and R. Donato, manuscript in
preparation). On the other hand and interestingly,
S100B has been recently shown to protect cells
from oxidative damage by sequestering copper ions
[42]. Together, these data would suggest that as long
as S100B is being kept within cells at physiological
levels of expression, the protein would exert a pro-
tective e¡ect, whereas once secreted its local concen-
tration would dictate its bene¢cial or detrimental ef-
fects. Also recently, oxidized monomeric S100B (i.e.
intrachain disul¢de crosslinked S100B monomer),
that forms on exposure of the protein to peroxyni-
trite anion (OONO3), was shown to act as a potent
astrocyte mitogenic factor at subnanomolar concen-
trations, its e¡ect being much larger than that ex-
erted by the disul¢de crosslinked S100B2 dimer
[272]. Whether or not intrachain disul¢de crosslinked
S100B monomer can form in vivo is not known yet.
S100B exists as a homodimer even at very low con-
centrations [68], and oxidation of monomeric and
dimeric S100B was shown not to occur under reduc-
ing conditions [272], suggesting that within cells in-
trachain and interchain disul¢de crosslinking of
S100B requires a remarkable alteration of the redox
status of C-68 and C-84 residues. While the non-re-
ducing conditions found extracellularly might favor
the formation of intrachain and interchain disul¢de
crosslinked S100B species, such an event has been
questioned, based on structural studies [77]. Yet,
since administration of S100B to cultured astrocytes,
neurons, and microglia causes de¢nite (trophic, mi-
togenic, toxic, and regulatory) e¡ects [51,236^
240,243^245,267^270,272], and unpublished observa-
tions), and since storage of S100B in the absence of
reducing agents results in the formation of disul¢de
crosslinked S100B dimers [52], future analyses should
elucidate the mechanism whereby intrachain and/or
interchain disul¢de crosslinked S100B is being gener-
ated in vivo. As mentioned above, interaction of
S100B with phospholipid bilayers (e.g. during the
process of S100B release to the extracellular space)
might alter the S100B conformation thereby deter-
mining disul¢de crosslinking in the protein [30,52].
Interestingly, oxidized S100B is an excellent substrate
of casein kinase II in vitro, the protein being phos-
phorylated at S-62, i.e. within its C-terminal Ca2-
binding loop, whereas S100A1 is not phosphorylated
[272]. Phosphorylation of S100B requires prior oxi-
dation, OONO3 being the most potent oxidizing
agent among those tested [272]. While phosphoryl-
ated S100B maintains its ability to stimulate glial
cell proliferation in an in vitro assay, attempts to
detected phosphorylated S100B in a glial cell line
proved unsuccessful [272]. Thus, it is at present un-
certain whether or not phosphorylation of S100B
does occur in vivo or is functionally relevant.
3.2.3. S100B and cognitive behavior
S100B has been implicated in the modulation of
learning and memory (Table 1). Injection of an anti-
S100 protein antiserum (likely an anti-S100B antise-
rum) into the rat brain was shown to cause memory
de¢cits for tasks involving transfer of handedness
[273], maze learning [274], and alimentary condi-
tioned re£ex [275], and injection into the hippocam-
pus inhibited long-term potentiation [276,277]. Also,
injection of monoclonal antibodies to S100A1 and
S100B into chick brain was shown to interfere a
few minutes after injection with the sequence of
events leading to the consolidation of passive avoid-
ance memory in a temporally distinct manner [278].
According to these studies, extracellular S100B
would play a role in memory processes, but the
mechanism whereby S100B acts is far from being
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elucidated. The fact that S100A1 also is implicated in
learning is di⁄cult to explain since there in no evi-
dence presented that S100A1 is released by glial or
neuronal cells. On the other hand, transgenic mice
overexpressing S100B show behavioral abnormal-
ities. S100B transgenic mice display decreased T-
maze spontaneous alternation rate [279] and nov-
elty-induced female-speci¢c hyperactivity [280].
Also, overexpression of S100B impairs, but does
not abolish, the ability to solve a spatial task [281],
and interferes with the spatial and temporal explor-
atory pattern [282,283]. These observations were put
in relation to the above described changes in S100B
levels in Alzheimer’s disease and Down’s syndrome
brains, but, again, the molecular mechanism(s)
underlying these abnormalities is(are) far from being
elucidated. Brains from S100B transgenic mice show
a higher density of dendrites in the hippocampus at
the earliest stages of postnatal development, com-
pared to controls, and a signi¢cant loss of dendrites
by one year of age suggestive of the presence of
neuro¢brillary tangles [284]. Again, S100B seems to
be bene¢cial at physiological concentrations, and
detrimental at higher concentrations, assuming that
overexpression of S100B is accompanied by an in-
creased release and accumulation of this protein in
the brain extracellular space, for which there is no
conclusive evidence presented thus far. Neuromodu-
lin, an S100B target protein (Table 1), has an impor-
tant role in neuronal development and plasticity (re-
viewed in [285]). Inhibition of neuromodulin
phosphorylation by S100B [90^92] might result in
regulation of the suggested activity of this protein
in neuronal development and plasticity, as PKC-de-
pendent phosphorylation of neuromodulin is linked
with both nerve-terminal sprouting and long-term
potentiation [285]. However, at present there is no
information on cellular and subcellular colocaliza-
tion of neuromodulin and S100B nor is there any
evidence that overexpression of S100B is accompa-
nied by a blockade of the suggested role of neuro-
modulin in nerve-terminal sprouting.
3.2.4. S100 proteins and in£ammation
A murine 10-kDa chemotactic protein, CP-10, dis-
playing 59% amino acid sequence identity to human
S100A8, exhibits potent chemotactic activity for
polymorphonuclear leukocytes and monocytes both
in vitro and in vivo (reviewed in [286]; also see
[287,288]). Although the cDNA sequence of murine
CP-10 is identical to that of murine S100A8 [289]
and both proteins have been associated with in£am-
mation, several di¡erences were reported concerning
the biological activity of the two proteins [286].
Thus, CP-10 is being referred to as the S100A8-like
CP-10 protein in the present review. This protein is
constitutively expressed in neutrophils, is not ex-
pressed by resting or activated lymphocytes, by ¢bro-
blasts or by unstimulated endothelial cells, but is ex-
pressed in macrophages and endothelial cells
activated by interleukin-1 and lipopolysaccharide
(LPS) [287^291]. It is suggested that the S100A8-
like CP-10 protein may contribute to ampli¢cation
of leukocyte recruitment [287] (Table 1). This implies
that the protein is being released by the cells that
express it. In fact, LPS-primed and challenged mac-
rophage RAW cells secrete the S100A8-like CP-10
protein [40], and a synthetic peptide derived from
the hinge region of the protein acts as a chemotactic
agent [93]. The S100A8-like CP-10 protein shows
many of the characteristics of pure chemoattractants,
including stimulation of actin polymerization in and
shape change of target cells without degranulation or
oxidative burst, similar to transforming growth fac-
tor-L1 [286,292]. As with all other S100 members
shown to be released into the extracellular space,
the mechanism whereby the S100A8-like CP-10 pro-
tein is secreted is largely unknown (also see below).
Other S100 members have been reported to display
chemotactic activity, i.e. S100A2, which was shown
to be active on eosinophils at subnanomolar concen-
trations and to interact with high a⁄nity with spe-
ci¢c binding sites on the surface of these cells [59],
and S100A7, which is chemotactic for CD4 lym-
phocytes [60] (Table 1).
In addition to chemotactic activities, some S100
members display cytostatic or antimicrobial activ-
ities. Thus, extracellular S100A8/S100A9 have been
reported to inhibit immature, mononmyelocytic HL-
60 cell proliferation and mitogen-stimulated lympho-
cyte proliferation [293,294], and to have cytostatic
activity towards bacteria/fungi [295]. Recent evidence
suggests that administration of S100B to a cytotoxic
lymphocyte cell line results in a dose-dependent de-
crease in proliferation rate and inhibition of interfer-
on-Q secretion [296]. Also, S100A9 inhibits macro-
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phage activation, likely in cooperation with other
factors such as interleukin-10 and transforming
growth factor-L [297], and inhibits immunoglobulin
synthesis by lymphocytes in vitro [298]. Thus,
S100A8/S100A9, that appear to play a role in mono-
cyte/macrophage maturation [152^154], once secreted
actually display anti-in£ammatory activities, as op-
posite to the pro-in£ammatory activity of the
S100A8-like CP-10 protein. Release of monocyte
S100A8/S100A9 is inhibited by interleukin-10 and
interleukin 4, but not by interleukin-3 [299]. Yet, it
has been recently reported that local skin inoculation
with the S100A8/S100A9 complex in the presence of
Ca2 caused extensive eosinophil accumulation [300],
and sustained increases in S100A8 and S100A9
mRNA expression were observed in in¢ltrating neu-
trophils in the early stage of the delayed type hyper-
sensitivity skin response (1 day) followed by a de-
crease in neutrophil S100A8 and S100A9 content
by 2^3 days [301]. These data were interpreted as
indicative of a pro-in£ammatory role of the two
S100 proteins [300,301]. Thus, further information
is required to precisely assess the biological role of
secreted S100A8 and S100A9.
Together, these observations suggest that, follow-
ing secretion or release into the extracellular space,
some S100 members might have a regulatory (either
activatory or inhibitory) role in the in£ammatory
response. It is not known at present how these
S100 proteins interact with target cells. As to the
signal transduction pathways that are being activated
in response to S100 interaction with target cells, the
few available data indicate that extracellular S100B
causes a sustained increase in cytosolic Ca2 via ac-
tivation of phospholipase C [249], stimulate the ex-
pression of proto-oncogenes [245], and induce iNOS
in astrocytes [270]. No information is available at
present about the signalling pathways activated by
the interaction of S100A8/S100A9, the S100A8-like
CP-10 protein, and S100A7 with responsive cells
(Fig. 3).
S100A8 and S100A9 have been recently reported
to be secreted by monocytes after activation of PKC
via a MT-dependent pathway, i.e. a mechanism dif-
ferent from the classical endoplasmic reticulum/Golgi
route and the alternative secretory pathway of the
interleukin-1L-type [61]. However, the relationship
between MT network integrity and S100A8/S100A9
secretion remains to be elucidated.
Binding of the S100A8/S100A9 heterocomplex, but
not individual proteins, to unsaturated fatty acids
has been put in relation to the regulatory role of
this protein complex in in£ammation [302,303]. Since
S100A8 and S100A9 are up-regulated in keratino-
cytes induced to di¡erentiate by extracellular Ca2
and in psoriatic keratinocytes [304^308], complexa-
tion of the S100A8/S100A9 heterodimer with unsat-
urated fatty acids could represent a way to modulate
the pro-in£ammatory action of arachidonic acid or
to target the heterodimer to membranes during the
S100A8/S100A9 secretion process [302,303].
Recently, S100A13 has been found associated with
an aggregate made of ¢broblast growth factor-1 and
synaptotagmin-1 and suggested to play a role in the
regulation of the release of this aggregate [309] (Ta-
ble 1). Since ¢broblast growth factor-1 has been im-
plicated in in£ammation, S100A13 was postulated to
be a functional component of the ¢broblast growth
factor-1 release pathway [309]. However, it is not
known whether S100A13 is also released into the
extracellular space and/or S100A13 serves to target
the ¢broblast growth factor-1-synaptotagmin aggre-
gate to plasma membranes during the release proc-
ess.
3.2.5. S100A10 and plasminogen activation
S100A10 has been reported to bind to plasmino-
gen via lysine residues (K-95 and K-96) in its C-ter-
minal extension and to stimulate tissue-type plas-
minogen activator (t-PA)-dependent plasminogen
activation either alone or as a complex with annexin
II [310] (Table 1). Consistently, a synthetic peptide
derived from S100A10 C-terminal extension blocks
the stimulation of t-PA-dependent plasminogen acti-
vation [310]. Also, S100A10 was shown to be essen-
tial for the protection of plasmin and t-PA from in-
activation by K2-antiplasmin and plasminogen
activator inhibitor type 1, respectively [310]. Thus,
S100A10 might play a role in the regulation of the
extrinsic pathway of blood coagulation. It was sug-
gested that S100A10 might be located on endothelial
cell surface, but the mechanism whereby S100A10
(and annexin II) is being translocated outside the
cell is still elusive [310]. Since the S100A10 C-termi-
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nal extension is critical for complexation with annex-
in II [31^33,36,69] and its last two lysine residues are
essential for S100A10 to interact with plasminogen
[310], then S100A10 should be complexed with an-
nexin II in such a way as K-95 and K-96 are avail-
able for interaction with plasminogen.
4. Regulation of expression of S100 proteins
S100B is synthesized during the G1 phase of the
cell cycle in glioma and melanoma cells [311,312]
with accumulation of the protein in the G0 phase
and cell di¡erentiation [313,314]. Synthesis of
S100B might thus be important for progression of
glioma and melanoma cells through the cell cycle.
Accordingly, inhibition of S100B synthesis results
in a decreased rate of glial cell proliferation [228].
The recent observation that S100B stimulates the ac-
tivity of Ndr [142], a kinase shown to be important
for cell division, also appears in line with the possi-
bility that S100B may have a role in the progression
of certain cell types through the cell cycle. Any pu-
tative role of S100B in cell-cycle progression likely is
developmentally regulated since the protein accumu-
lates during di¡erentiation in cell cultures [313,314].
Also, an S100 family member, probably S100B, ac-
cumulates at a very fast rate in the mouse nervous
system during the second and third postnatal week
[315], and in rat, rabbit and guinea pig cerebrum
during the third and fourth postnatal week [316^
318], in coincidence with the maximal increment in
the number of synapses [319]. Decreased expression
of both S100B protein [320] and S100B mRNA [321]
in crushed or transected rat sciatic nerve with resto-
ration of their normal levels following nerve regen-
eration has been documented. De-di¡erentiation and
proliferation of Schwann cells in injured nerves were
proposed as the cause of the above changes
[320,321]. Thus, S100B might be important in both
cell proliferation and cell maturation by acting on
di¡erent target proteins. These observations also sug-
gest that the S100B gene expression is under complex
transcriptional regulation. Previous and recent work
has shown that the rat, mouse and human S100B
gene is regulated by both positive and negative se-
quences located upstream in the 5P £anking DNA
regions [322^324]. The human S100B promoter is
contained within the 3167/+697 region of the gene
and its expression is variable among a number of cell
lines, but is not restricted to a de¢nite cell type or
species [321]. Unlike the positive regulatory elements
of the rat and mouse S100B gene that were reported
to be speci¢c to glial cells [322,323], the positive reg-
ulatory elements of the human gene appear cell line-
speci¢c [324]. Also, while a previous study concluded
that the negative regulatory elements of the mouse
S100B gene function only in non-glial cells [322], the
human S100B gene expression may be constitutively
repressed in all cell types by negative regulatory ele-
ments, implying that the expression of S100B in a
given cell type requires induction of an appropriate
factor that counters the action of that element [324].
Such a mechanism would allow a controlled expres-
sion of S100B in de¢nite cell types or in the same cell
type depending on the cell’s functional states. The
recent observations that S100B is being expressed
in cardiomyocytes post-infarction [131] and in repli-
cating myoblasts and immature myotubes [175],
whereas it is substantially absent in mature striated
muscle cells [138,139], appear to support the above
view. Also, the presence of both positive and nega-
tive regulatory elements upstream of the human
S100B promoter would provide a means to achieve
an optimal S100B expression level in a given cell
[324]. Several factors have been shown to regulate
the S100B expression. (i) Increases in the intracellular
levels of cAMP resulting in an increased synthesis of
S100B in rat C6 glioma cells [325^328], and cAMP
have been reported to control the expression of the
S100B gene in parallel with the expression of the
GFAP gene in the subpopulation of RT4 neuroglial
cell line capable of acquiring a glial-like phenotype,
but not in the subpopulation capable of acquiring a
neuronal-like phenotype [328]. A putative cAMP re-
sponse element has been found in the human S100B
gene [329]. (ii) Dexamethasone causes a biphasic re-
sponse in the levels of S100B mRNA in cultured rat
hippocampal astrocytes, i.e. an increase during the
¢rst 24 h of treatment which is followed by a signi¢-
cant decrease thereafter, with no changes in the levels
of intracellular S100B during the ¢rst 24 h and a
signi¢cant decrease thereafter [330]. (iii) Basic ¢bro-
blast growth factor-2 also causes a decrease in the
S100B mRNA levels in cultured rat cerebral cortex
astrocytes after a short-term treatment which is fol-
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lowed by a remarkable increase after a long-term
treatment likely due to changes in the rate of gene
transcription [331]. These changes are accompanied
by only a slight, if any decrease in the S100B protein
content of astrocytes during the ¢rst 3 days of treat-
ment, which is followed by a several-fold increase
thereafter [331]. (iv) In contrast, in the same cells
(cortical astrocytes) interleukin-1L causes suppres-
sion of S100B mRNA after both short- and long-
term treatment with no signi¢cant decrease in the
S100B protein levels [331], and treatment with
both, basic ¢broblast growth factor-2 and interleu-
kin-1L, results in a synergistic e¡ect [331]. Thus,
whereas basic ¢broblast growth factor-2 appears to
regulate the expression of S100B, no de¢nite role can
be ascribed to interleukin-1L as far as S100B expres-
sion is concerned. (v) L-Amyloid stimulates the syn-
thesis of both S100B mRNA and S100B protein in
C6 glioma cells and primary astrocyte cultures [259].
See above for implications of increased S100B ex-
pression in neurodegenerative disorders.
S100A6 was originally identi¢ed in ¢broblasts in-
duced to progress from the G0 to the G1 phase of the
cell cycle and thus suggested to be involved in cell-
cycle progression [332]. However, as in the case of
S100B, the increase in S100A6 mRNA during reti-
noic acid-induced cell di¡erentiation (but not in cells
induced to stop proliferating by serum starvation),
suggests that the S100A6 gene also is under complex
transcriptional regulation and that the S100A6 gene
has a bifunctional role, being expressed in both pro-
liferating and di¡erentiating cells [333]. The increased
expression of S100A6 in proliferating cells depends
on the binding of the heat-shock element and SV40
enhancer to the promoter region of the S100A6 gene
[334], whereas the increased expression of the protein
in retinoic acid-treated, di¡erentiating cells depends
on increased binding of the transcription factor AP-1
to the 3161/3135 promoter region of the S100A6
gene [335].
The murine S100A1 gene also is under complex
transcriptional control [336]. A positive regulatory
element was found in the S100A1 promoter region
in a skeletal muscle cell line between 31600/31081.
In a glial cell line and in a neuronal cell line these
same sequences were negative and neutral, respec-
tively, suggesting that this region has a major role
in targeting S100A1 expression to speci¢c cell types.
As with S100B [228], inhibition of S100A1 synthesis
results in a decreased rate of proliferation of PC12
cells [178]. Interestingly, although less active that
S100B, S100A1 also stimulate the Ndr kinase activity
[142].
Up-regulation of the S100A4 and S100A10
mRNAs in proliferating Schwann cells in crushed
or transected rat sciatic nerve with their subsequent
down-regulation after nerve regeneration has been
reported [321]. These observations suggest that
S100A4 and S100A10 have a (yet unknown) role in
de-di¡erentiated, proliferating Schwann cells. The
genes of these two proteins have been shown to be
induced by nerve growth factor in cultured neurons
[337].
5. S100 proteins in tumor cells
S100A4, S100A6, S100A7 and S100B are up-regu-
lated in several human tumor cells ([22,23,335,338,
339], and references therein). S100A4 has attracted
much attention in this regard. S100A4 was originally
identi¢ed as a protein induced when cultured rat
mammary epithelial cells change to an elongated my-
oepithelial-like cell [340]. However, elevation of
S1004 or its mRNA can be observed in serum-in-
duced increase in growth rate of cultured murine
¢broblasts [341], oncogene- or carcinogen-induced
transformation of murine ¢broblasts [342], or rat
kidney cells [343]. A positive correlation was found
between the metastatic potential of murine mammary
adenocarcinoma cell lines and the level of expression
of S100A4 mRNA [344,345] and B16 melanoma cells
[346]. Also, expression of S100A4 in MMTV-neu
transgenic mice induces metastasis of mammary tu-
6
Fig. 4. Summary of intracellular and extracellular functional roles of S100 proteins. Within cells S100 proteins may participate in the
regulation of a large variety of cell activities, as indicated. Members of the S100 family that have been shown to be released into the
extracellular space, albeit with mechanisms that remain to be elucidated, would exert e¡ects on a number of cell types, thereby regu-
lating their activities as detailed in the text (also see Fig. 3).
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mors [347] and expression of antisense RNA to
S100A4 gene in high-metastatic A11 cells suppresses
cell motility and in vitro invasiveness [348]. These
¢ndings strongly suggest that S100A4 has an impor-
tant role in the acquisition of metastatic phenotype,
although the molecular mechanism whereby S100A4
operates is largely unknown [349]. Interaction of
S100A4 with non-muscle tropomyosin and myosin
[130,222,223] and F-actin [224^226] and structural
changes in anchoring junctions [345] have been pro-
posed as possible mechanism by which S100A4 in-
creases the invasiveness of tumor cells. The recent
observation that S100A4 inhibits myosin heavy chain
phosphorylation by PKC [130] and previous studies
showing that PKC-dependent phosphorylation of
myosin heavy chain results in inhibition of myosin
heavy chain assembly [350,351] may indicate that
S100A4 is implicated in the regulation of cell motility
and, hence, invasiveness of metastatic cells via inter-
action with myosin heavy chain. Demethylation of a
CD3N enhancer in the ¢rst intron of the murine
S100A4 gene has been proposed as a possible mech-
anism of increased expression of this protein in meta-
static cells [352].
S100A1 and S100B, which are known to be over-
expressed in human cancers [22], have been suggested
to have a role in the activation of the Ndr kinase
activity, and a positive correlation has been found
between hyperactivation of Ndr and overexpression
of S100B in melanomas [142].
By contrast, S100A2 in markedly down-regulated
in breast tumor biopsies and can be re-expressed in
mammary carcinoma cells by azadeoxycytidine treat-
ment [353]. These ¢ndings suggest that S100A2 might
have a tumor suppressor function [354], a suggestion
supported by the observation that the proximal pro-
moter region of the S100A2 gene is unmethylated in
normal but hypermethylated in tumorigenic cells
[355]. Overall, these data indicate that, although the
genes coding for S100A1 to S100A13 are tightly clus-
tered on the human chromosomal region 1q21
[356,357], individual S100 genes in this chromosomal
region are di¡erentially regulated.
6. Conclusions
S100 proteins have been implicated in the regula-
tion of several intracellular activities, e.g. protein
phosphorylation, enzymes involved in energy metab-
olism, the cAMP and cGMP signalling pathways, the
in£ammatory response, the cycle of contraction-re-
laxation, Ca2 homeostasis, the dynamics of cyto-
skeleton constituents, and cell proliferation (includ-
ing neoplastic transformation) and di¡erentiation
(summarized in Fig. 4). No knock-out animal model
has been obtained thus far for any S100 member.
Thus, it is di⁄cult at present to draw conclusions
as to whether or not any putative function attributed
to an S100 protein in vitro also occurs in vivo. How-
ever, in vitro e¡ects of S100 proteins on protein
phosphorylation, some enzyme activities, Ca2 ho-
meostasis, activities of certain transcriptional factors
and cytoskeleton dynamics likely re£ect in vivo reg-
ulatory functions of some S100 members. Although
in a limited number of cases some S100 members
share certain target proteins, in most cases target
protein speci¢city has been documented, suggesting
that individual S100 members display speci¢c regu-
latory properties. Accordingly, a high degree of cel-
lular speci¢city has been observed in terms of protein
expression. With a few exceptions, S100 proteins
likely exist as homodimers (and heterodimers, in
some cases) within cells. Structural data indicate
that in dimeric S100 proteins, the two monomers
are related by a two-fold axis of rotation, thus ex-
hibiting a three-dimensional structure not found in
other Ca2-binding proteins. These data and other
experimental evidence suggest that, upon Ca2 bind-
ing, S100 dimers crossbridge two homologous or het-
erologous target proteins, as in an S100 dimer at
least two binding sites are located on opposite sides.
The available evidence suggests that several regions
contribute to the formation of functional (either
Ca2-dependent or Ca2-independent) binding sites
on monomers of an S100 dimer, which could explain
the ability of a given S100 protein to interact with
distinct and structurally unrelated target proteins.
Also, the relative concentrations of an S100 protein
and its target protein(s) at a speci¢c cell site, as well
as the a⁄nity of their binding, would be critical to
the regulatory e¡ects of S100 proteins. Some S100
members are released or secreted and act extracellu-
larly. Released S100 proteins appear to exert trophic
or toxic e¡ects on, e.g. neurons and astrocytes, de-
pending on their concentration, act as chemoattrac-
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tants towards leukocyte recruitment, modulate the
proliferation of certain target cells, or regulate the
activation state of, e.g. macrophages. Thus, some
S100 proteins might act from outside the cell to par-
ticipate in tissue organization during development,
the in£ammatory response, and/or tissue remodelling
in speci¢c pathological states. However, the mecha-
nism of S100 protein secretion/release, the factors
that regulate S100 protein secretion/release, and the
molecular mechanisms whereby released S100 pro-
teins interact with and the signalling pathways they
activate within their target cells are largely unknown
at present. While further analyses should ascertain
the physiological relevance of the in vitro functions
of S100 proteins thus far discovered and the mecha-
nisms whereby individual S100 members operate,
S100 proteins appear to play important regulatory
roles both within and outside cells.
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